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Abstract
A new class of severe but treatable autoimmune encephalitides is associated with serum and CSF
autoantibodies to cell surface receptors that are thought to cause disease by disrupting the normal function of
their target protein. Consistent with disruption of the major neurotransmission pathways and thus circuit
malfunction in the central nervous system, symptoms of these newly characterized diseases are severe and
include psychosis, memory loss, confusion, seizures, and autonomic instability normal function. The majority
of symptoms resolve with aggressive immunosuppresive therapy.
The best characterized of these encephalitides is associated with antibodies to ionotropic glutamate receptors,
N-methyl-D-aspartate receptor (NMDAR) or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor (AMPAR). NMDAR and AMPAR autoantibodies cross-link the cognate synaptic receptors on the
surface of cultured neurons and result in a selective internalization of the target without disruption of any
other synaptic component or injury to neurons. In a passive transfer animal model, chronic perfusion of
NMDAR antibodies into the cerebrospinal fluid (CSF) of mice also decreases NMDA receptors after 14 days,
which results in anhedonia and diminished spatial memory. Consistent with the reversible course of disease,
the effects of NMDAR and AMPAR autoantibodies can be reversed in both in vivo and in vitro model
systems. These mechanisms may underlie the neurological and psychiatric manifestations of these forms of
autoimmune encephalitis, and account for recovery of many patients with immune therapy aimed at lowering
antibody titer.
Patients with antibodies to the metabotropic gamma-aminobutyric acid receptor type B (GABAB receptor)
develop severe intractable seizures, but little is known about the underlying pathophysiological mechanisms.
Deletion mapping and expression in heterologous cells showed that patient anti-GABAB antibodies bind to
alternatively spliced Sushi domains present in the presynaptically localized GABAB1a isoform. In contrast to
patient anti-NMDAR antibodies, GABAB autoantibodies did not result in a decrease in surface GABAB
receptors or their internalization. Treating neurons with GABABR autoantibodies for two hours blocked the
activation of GABAB receptors by baclofen in a titer-dependent manner. Autoantibody-bound GABABRs are
still signaling competent, because baclofen block was circumvented by directly activating GABAB2 with a
selective agonist, CGP7930.
Patient GABAB receptor autoantibodies are selective GABAB1 antagonists that may contribute to seizures by
interfering with GABA-mediated inhibition. Brain penetrant GABAB2 agonists may be useful to treat
intractable seizures in anti-GABAB receptor encephalitis patients.
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ABSTRACT 
SYNAPTIC, CELLULAR AND BEHAVIORAL PATHOPHYSIOLOGY IN ANTI-GABAB 
RECEPTOR AND ANTI-NMDA RECEPTOR ENCEPHALITIDES 
 
Ankit Jain 
Rita J. Balice-Gordon 
 
A new class of severe but treatable autoimmune encephalitides is associated with 
serum and CSF autoantibodies to cell surface receptors that are thought to cause 
disease by disrupting the normal function of their target protein. Consistent with 
disruption of the major neurotransmission pathways and thus circuit malfunction in the 
central nervous system, symptoms of these newly characterized diseases are severe 
and include psychosis, memory loss, confusion, seizures, and autonomic instability 
normal function. The majority of symptoms resolve with aggressive immunosuppresive 
therapy. 
The best characterized of these encephalitides is associated with antibodies to 
ionotropic glutamate receptors, N-methyl-D-aspartate receptor (NMDAR) or α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR). NMDAR and AMPAR 
autoantibodies cross-link the cognate synaptic receptors on the surface of cultured 
neurons and result in a selective internalization of the target without disruption of any 
other synaptic component or injury to neurons. In a passive transfer animal model, 
chronic perfusion of NMDAR antibodies into the cerebrospinal fluid (CSF) of mice also 
decreases NMDA receptors after 14 days, which results in anhedonia and diminished 
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spatial memory.  Consistent with the reversible course of disease, the effects of NMDAR 
and AMPAR autoantibodies can be reversed in both in vivo and in vitro model systems. 
These mechanisms may underlie the neurological and psychiatric manifestations of 
these forms of autoimmune encephalitis, and account for recovery of many patients with 
immune therapy aimed at lowering antibody titer. 
Patients with antibodies to the metabotropic gamma-aminobutyric acid receptor 
type B (GABAB receptor) develop severe intractable seizures, but little is known about 
the underlying pathophysiological mechanisms. Deletion mapping and expression in 
heterologous cells showed that patient anti-GABAB antibodies bind to alternatively 
spliced Sushi domains present in the presynaptically localized GABAB1a isoform.  In 
contrast to patient anti-NMDAR antibodies, GABAB autoantibodies did not result in a 
decrease in surface GABAB receptors or their internalization. Treating neurons with 
GABABR autoantibodies for two hours blocked the activation of GABAB receptors by 
baclofen in a titer-dependent manner. Autoantibody-bound GABABRs are still signaling 
competent, because baclofen block was circumvented by directly activating GABAB2 with 
a selective agonist, CGP7930.   
Patient GABAB receptor autoantibodies are selective GABAB1 antagonists that may 
contribute to seizures by interfering with GABA-mediated inhibition. Brain penetrant 
GABAB2 agonists may be useful to treat intractable seizures in anti-GABAB receptor 
encephalitis patients. 
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PREFACE 
Recently, several novel, potentially lethal and treatment-responsive syndromes that 
affect hippocampal and cortical function have been shown to be associated with auto-
antibodies against synaptic antigens, notably glutamate or GABAB receptors. Patients 
with these autoantibodies (sometimes associated with teratomas and other neoplasms) 
present with psychiatric symptoms, seizures, memory deficits and decreased levels of 
consciousness. These symptoms often improve dramatically after immunotherapy or 
tumor resection. In this work I review and extend several studies of the cellular and 
synaptic effects of these antibodies in hippocampal neurons in vitro and preliminary work 
in rodent models. Our work suggests that patient antibodies lead to rapid and reversible 
removal of neurotransmitter receptors from synapses, leading to changes in synaptic 
and circuit function that, in turn, are likely to lead to behavioral deficits. I also discuss 
several of the many questions raised by these and related disorders. Determining the 
mechanisms underlying these novel anti-neurotransmitter receptor encephalitides will 
provide insights into the cellular and synaptic bases of the memory and cognitive deficits 
that are hallmarks of these disorders, and potentially suggest avenues for therapeutic 
intervention. 
In my thesis, I have focused on the pathophysiological mechanisms of two 
autoimmune encephalitides, one associated with anti-NMDA receptor antibodies, and 
the other associated with anti-GABAB receptor antibodies. The investigation of these 
diseases ranges from patient-oriented research to mechanistic experiments in cell 
culture and in animal models. The rich tapestry of clinical and mechanistic insights into 
this new class of diseases caused by neuronal cell surface autoantibodies is 
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introduced in Chapter 1. Rapid progress has been made in our understanding of these 
diseases since the discovery of anti-NMDA receptor encephalitis as the founding 
member of this class of autoimmune disease in 2003. Since then, many previously 
known as well as newly identified syndromes have been found to be caused by 
autoantibodies to a diverse group of surface proteins such as neurotransmitter 
receptors, synaptic scaffolding proteins, and also proteins whose function has not yet 
been discovered.  
In Chapter 2, I explore the mechanistic underpinnings of pathogenesis by GABAB 
autoantibodies in a neuronal cell culture model. The autoantibodies in anti-GABAB 
receptor encephalitis affect GABAB receptor function by a mechanism distinct from what 
has been described thus far for anti-NMDA receptor, anti-AMPA receptor and anti-
GABAA receptor encephalitis. Rather than decreasing the level of GABAB receptors at 
the surface of neurons, GABAB autoantibodies directly antagonize the activation of 
GABAB receptors. 
In Chapter 3, I present a multi-center collaborative effort to generate and describe a 
passive immunization model of anti-NMDA receptor encephalitis. My role in this work 
was to generate the animal model, and discover the conditions and tools that resulted in 
a successful infusion of anti-NMDA receptor encephalitis patient CSF into mouse 
cerebral ventricles. Like in vitro, exposure of mouse brains to patient CSF reduces 
NMDA receptor levels and results in defects in spatial and object memory. Remarkably, 
both the reduction in NMDA receptor levels and the cognitive decline recovers after the 
cessation of patient CSF infusion. This animal model will be vital to test potential 
therapeutic interventions that may reduce receptor loss and cognitive decline or hasten 
recovery. 
In Chapter 4, I describe a small case series of the first known pregnant 
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women with anti-NMDA receptor encephalitis. The two term infants potentially exposed 
to anti-NMDA receptor antibodies in utero did not have any signs of encephalitis.  
The importance of these disorders is that they offer human models of brain–
immune interactions in which the target antigens have critical roles in neuronal synaptic 
transmission and plasticity. Therefore, their study will improve our understanding of the 
effects of the antibodies at the cellular, synaptic and circuit levels, eventually impacting 
the clinical management of the patients.
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CHAPTER 1. Introduction 
Cellular, synaptic and circuit effects of antibodies in synaptic 
autoimmune encephalitides 
 
Ankit Jain1 and Rita Balice-Gordon1,2 
 
1Department of Neuroscience, Perelman School of Medicine at the University of 
Pennsylvania, Philadelphia, PA  19104 
2Neuroscience Research Unit, Pfizer, Inc., Cambridge, MA  02139 
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Establishing a pathogenic role for anti-synaptic antibodies 
Multiple lines of evidence strongly suggest that anti-synaptic antibodies are not 
simply markers of disease but rather are directly pathogenic.  When live, 
unpermeabilized dissociated rodent brain cells are treated with patient CSF, 
immunoglobulins (IgG) isolated from patient CSF or serum, unique patterns of punctate 
surface staining are observed (Fig. 2A; Ances et al., 2005). This shows that patient 
derived antibodies bind distinct neuronal cell surface proteins. This is in contrast to 
classically described paraneoplastic autoimmune encephalitides, in which the isolated 
antibodies target intracellular antigens, resulting in a cytotoxic T cell response, neuronal 
cell death and a result, poor prognosis (Dalmau and Rosenfeld, 2008). In the case of 
synaptic autoimmune encephalitides rodent brain sections immunostained with patient 
CSF also show distinct patterns of immunoreactivity in the neuropil of hippocampus, 
cortex and other brain regions, while there is no immunoreactivity to neuronal cell bodies 
(Vitaliani et al., 2005).  Brain biopsies from a small number of patients demonstrate 
minimal pathologic changes or cell loss but demonstrate rare T cell and B cell infiltrates, 
microgliosis and astrocytosis (Fig. 4; Martinez-Hernandez et al., 2011). These results 
are consistent with a direct pathogenic role for patient antibodies in synaptic 
autoimmunities rather than a cell mediated immune response as seen in paraneoplastic 
encephalitides associated with intracellular antigens.   
Mass spectrometry has been particularly useful for identifying specific binding 
targets of anti-synaptic antibodies from immunoprecipitates of rat brain lysates with 
patient antibdodies (Fig. 2C; Lai et al., 2009; Lancaster et al., 2011). Immunostaining of 
heterologous cells that overexpress an antigenic candidate protein identified by mass 
spectrometry with patient CSF has been used to confirm binding of patient antibodies to 
a particular antigenic protein (Fig. 2D-F). These in vitro approaches, 
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together with other analyses, have been used to establish that each distinct syndrome 
corresponds to a distinct cell surface antigen targeted by patient CSF antibodies (Fig. 1). 
The function of a surface protein antigen and the particular neuropsychiatric 
encephalitis syndrome associated with that antigen are, not surprisingly, strongly 
correlated.  Moreover, the titer of a specific antibody is correlated to disease severity. 
Upon aggressive immunomodulation therapy, these patient often improve in concert with 
a decrease in antibody titer of the CSF (Dalmau et al., 2008; Florance et al., 2009), 
although many patients can have positive antibody titers several years after their 
recovery.  Work from several labs has shown that associated antibodies likely cause the 
neuronal and circuit abnormalities that manifest as neuropsychiatric symptoms, using 
several complementary approaches.  
In assays of antibody-antigen binding that rely on immunoprecipitation or 
radioligands, it is not possible to distinguish between binding of antibody directly to the 
protein of interest or to a non-antigenic protein that is bound to the antigenic protein in a 
multiunit complex. To show that the putative target antigen is indeed sufficient to bind 
patient antibodies, it is important to demonstrate that patient antibodies can immunostain 
heterologous cells exogenously expressing the putative target antigen, and do not bind 
to heterologous cells not expressing the exogenous protein.  The CSF of autoimmune 
encephalitis patients may contain antibodies against several distinct antigens, and the 
results from immunoprecipitation, neuronal staining and heterologous cell staining would 
be consistent with the possibility of antibodies to multiple antigens. To show that the 
putative target antigen is specific and necessary to bind to immunoglobulins in a 
patient’s CSF, a demonstration that patient antibodies do not bind to neuronal tissue 
from rodents that lack the target antigen is required (Fig. 1). 
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Another confounding factor is that any effect of CSF on neurons in vitro or in vivo 
may be the result of some factor(s) other than self-reactive immunoglobulins that does 
not specifically bind to the putative target, for example elevated cytokines and other 
sequelae of inflammation. To show that the immunoglobulin fraction of the CSF is 
necessary and sufficient to disrupt normal functioning of the target antigen, one needs to 
demonstrate that the effect of CSF is reproduced by IgG purified from CSF, but not by 
the CSF fraction depleted of IgG. To confirm that antibodies cause neuronal dysfunction 
and hence are the most likely candidate CSF factor to cause disease, the specific 
antibodies are purified from CSF by incubation with immobilized antigen. Treatment with 
this immunodepleted CSF results in no adverse effects on neurons, while the specific 
antibodies purified from patient CSF recapitulate the effect of whole patient CSF. The 
specific binding of antibodies along with an isolated change in the properties of the 
cognate antigen provides a plausible biological mechanism for the causal link between 
patient antibodies and the neuropsychiatric manifestation of the associated disease.   
Cellular and synaptic mechanisms mediated by antibodies  
Antibodies against ionotropic glutamate receptors 
The best characterized autoimmune encephalitides in patients as well as in the 
laboratory are ones associated with antibodies to ionotropic glutamate receptors: NMDA 
receptors (NMDAR) and AMPA receptors (AMPAR).  Anti-NMDAR encephalitis patients 
classically present with severe aggression, paranoia, hallucinations and delusions 
characteristic of acute psychosis along with personality changes and memory loss 
(Dalmau et al., 2007; Sansing et al., 2007). Within days or weeks of the appearance of 
psychiatric symptoms, patients begin to deteriorate neurologically; they have debilitating 
seizures, decreased level of consciousness, abnormal movements, autonomic instability, 
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and hypoventilation. In contrast to the varied symptoms in anti-NMDAR encephalitis, 
anti-AMPAR encephalitis most often presents with isolated memory loss and seizures 
(Lai et al., 2009). 
Both NMDARs and AMPARs transmit glutamatergic excitation, but serve distinct 
functions at the cellular and circuit level.  AMPA receptors mediate most of the fast 
excitatory synaptic transmission in the brain (Shepherd and Huganir, 2007), while 
NMDARs act as molecular coincidence directors.  Open NMDARs allow calcium to enter 
the postsynaptic cell where the high local concentration of calcium acts as a second 
messenger. Together, they are essential for synaptic plasticity and memory.  
NMDA receptors are usually formed from heteromers of two NR1 and two NR2 
subunits (Kendrick et al., 1996; Laube and Kiderlen, 1997).  There are four NR2 subunits 
(NR2A-D), which have 50-70% sequence identity in the extracellular domain; NR1 is 
ubiquitously distributed in the brain (Monyer et al., 1994; Standaert et al., 1994; Waxman 
and Lynch, 2005).  AMPA receptors are predominantly heterotetramers composed of 
GluR1, 2, 3 or 4 subunits, and distinct combinations of subunits are expressed in a 
region-specific manner (Palmer et al., 2005).  GluR1/2 and GluR2/3 levels are high in 
hippocampus and other limbic regions (Sprengel, 2006), similar to the distribution of 
immunostaining with patients' antibodies.  
There are several possible molecular mechanisms by which antibody binding to 
synaptic proteins may result in a disruption in synaptic transmission that in turn alters 
circuit properties pathologically. Antibody binding may block the agonist binding site or 
inhibit conformational changes that promote the activation of receptors. In a classically 
known autoimmune disease of the neuromuscular synapse, myasthenia gravis, 
application of the pathogenic antibodies against nicotinic acetylcholine receptor 
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(nAChRs) from patients to outside-out patches of mouse myotubes irreversibly blocks 
AChR currents (Jahn et al., 2000). In addition to agonist binding sites, both AMPAR and 
NMDAR have additional N-terminal binding sites for channel modulators such as zinc 
and polyamines that may be obscured by patients' antibodies (Rassendren et al., 1990; 
Herin and Aizenman, 2004; Paoletti and Neyton, 2007).  
On the opposite end of the spectrum, the antibodies may promote the active 
conformation of the antigenic receptor and thus result in a constitutive or increased 
activity of the receptor.  NMDA receptor NR2 subunit specific antibodies from patients 
with systemic lupus erythematosus (SLE) cause neuronal death when injected into 
mouse brain (DeGiorgio et al., 2001). This effect is attenuated by treatment with the 
NMDAR blocker, MK-801, suggesting the antibodies mediate cell death by enhancing 
channel activation (DeGiorgio et al., 2001). Synaptic transmission is finely tuned over 
many episodes of concurring electrical and biochemical activity in the cell. A change in 
the gain of synaptic transmission by an exogenous agent can result in the loss of 
information encoded by the synapse or even result in cellular injury from excitotoxicity or 
increased intracellular calcium levels.  Thus, either activation or inhibition of the cognate 
receptor by antibodies may disrupt circuit dynamics by changing the finely tuned 
synaptic gain or by causing cellular injury. 
If antibody binding does not change the properties of the cognate antigen at the 
molecular level, it can result in clustering of target receptors and their consequent 
displacement from their multiprotein complexes at the synapse. This can change target 
antigen localization in synaptic domains, deplete the target antigen by antibody mediated 
capping and internalization, or even alter the turnover or intracellular trafficking of the 
target antigen (Fig. 3A-C).  Any of these possibilities would result in a loss of the role of 
the target receptor at synapses and hence adversely affect synaptic 
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transmission.  In addition to an acute blockade of nAChR by pathogenic antibodies, 
nAChR antibodies from patients with myasthenia gravis have also been observed to 
cause a loss of surface nAChRs by cross-linking and internalization (Drachman et al., 
1978). Similarly, cross-linking and internalization of voltage gated calcium channels by 
autoantibodies has also been shown to occur in patients with Lambert-Eaton syndrome 
(Nagel et al., 1988; Peers et al., 1993).  
In the anti-glutamate receptor encephalitides, incubation of cultured neurons with 
patient CSF for 15-30 minutes does not change synaptic transmission mediated by 
NMDARs or AMPARs (Moscato et al., 2014, Peng et al., 2014). However, both anti-
NMDAR1 and anti-AMPAR antibodies decrease the frequency and amplitude of mini 
EPSCs (Hughes et al., 2010; Moscato et al., 2014; Peng et al., 2014) within 12 hours of 
CSF treatment. This loss of glutamatergic signaling at the synapse after several hours of 
exposure of neurons to patient CSF is due to a reversible loss of receptors from 
synapses. For both diseases, incubation of neurons grown 14 to 21 days in vitro and 
treated with patient CSF for as little as 12 hours results in a titer-dependent decrease in 
density of synaptic receptors monitored by immunostaining (Fig 3D-E). There is also a 
decrease in the amount of surface receptors as seen by surface biotinylation followed by 
western blotting, and a consistent decrease in receptor clusters that colocalize with other 
synaptic proteins as assayed by immunostaining (Hughes et al., 2010; Moscato et al., 
2014). The receptors lost from the surface are internalized because a pool of antibody 
bound receptors can be stained only upon permeabalization of the cell (Fig. 3B-C; 
Moscato et al., 2014). 
The molecular and subcellular effects of patient CSF on NMDA and AMPARs are 
specific to the antigenic target of autoantibodies. The receptors are lost from the 
synapse without affecting neuron morphology, synapse density or the 
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surface localization or amount of other synaptic proteins. In anti-NMDAR encephalitis, 
despite a loss of NMDARs from synapses, there is no evidence for neuronal death, 
synaptic pruning, or a loss of AMPARs or GABARs at either glutamatergic or gabaergic 
synapses (Hughes et al., 2010). Similarly, anti-AMPAR antibodies exclusively affect 
synaptic AMPARs, without a decrease in PSD-95, vesicular glutamate transporter, 
NMDARs, or the AMPAR scaffolding protein, stargazin (Peng et al., 2014). This precise 
molecular excision of the target antigen from synapses reflects the specificity of anti-
target antibodies.   
Remarkably, the synaptic loss of NMDARs or AMPARs is reversible.  After 
incubation for 24 hours, CSF can be washed out and replaced with culture medium. In 
both cases, the cluster density of NMDARs or AMPARs returned to baseline within 
several days. This reversibility of loss of synaptic glutamate receptors, together with the 
fact that there is little or no neuron death after treatment with patient antibodies, may 
explain the remarkable recovery of patients after CSF antibody titers are lowered by 
immunotherapy. It is unclear, however, whether the prolonged time of recovery (usually 
several months) represents persistence of the immune response in the brain or slow 
recovery of circuit dysfunction caused by the decrease of synaptic proteins like NMDARs 
and AMPARs that are critical for synaptic function and plasticity. 
More is known about the mechanism of synaptic loss of NMDARs and AMPARs 
than other antigens.  NMDARs that are lost from the surface are internalized into 
recycling endosomes and to some degree in degradation lysosomes (Moscato et al., 
2014). This internalization effect of patient antibodies can be lost if the antibodies are 
converted into Fab fragments and lose their divalency (Fig. 2H).  The divalency seems to 
be more important than the presence of the Fc domain as clustering the NMDAR bound 
Fab fragment with a second divalent anti-Fab antibody restores the ability of 
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the pathogenic antibodies to internalize NMDAR (Hughes et al., 2010). This requirement 
for divalency of the antibody-antigen complex results in the sequestering of receptors in 
clusters and this signals internalization of the receptor clusters. In vitro immunostaining 
of neurons shows that treatment with patient CSF not only reduces the density of 
receptor clusters, but the remaining clusters are much larger than in control treated 
cultures. So, patient antibodies in anti-NMDAR encephalitis disrupt NMDAR contribution 
to glutamatergic synapses by their clustering effect, and may not need to agonize or 
antagonize NMDARs directly to cause the circuit dysfunction from abnormal 
glutamatergic signaling in anti-NMDAR encephalitis. One suggested mechanism for how 
antibody clustering of NMDAR results in their internalization is that upon antibody 
binding, NMDARs have a weaker interaction with the EphB2 receptor (Mikasova et al., 
2012), which stabilize and retain NMDARs at synapse (Dalva et al., 2000, 2007). This 
effect is strengthened several fold when EphB2Rs are activated by the ligand ephrin-B2. 
In fact, exposing neurons to ephrin-B2 along with the pathogenic antibodies partially 
rescues the antibody-dependent internalization and loss of NMDARs both in vivo and in 
vitro (Mikasova et al., 2012).  Measuring the diffusion of single particles using quantum 
dot imaging showed that when the NMDAR-EPHB2R complex is disrupted, NMDAR 
lateral mobility in the membrane is increased and NMDARs redistribute from being 
synaptically clustered to uniformly and diffusely distributed between the synaptic and 
extrasynaptic domains. Consistent with the observation that treatment with patient CSF 
reduces NMDAR density without affecting other synaptic components (Hughes et al., 
2010), treatment with NMDAR antibodies has no effect on surface diffusion of GluA1, 
metabotropic dopamine receptor D1, alpha2 GABAAR subunits, or Kv1.3 (Mikasova et 
al., 2012).  
Another mechanism for cellular and tissue damage seen in other 
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autoimmune diseases is opsonization of cells with autoantibodies followed by 
complement mediated inflammatory cytotoxicity. Muscle biopsies from patients with 
myasthenia gravis have revealed extensive deposits of components of the complement 
cascade (Engel et al., 1977; Sahashi et al., 1980). Autopsy and in vitro studies have also 
linked complement activation with Rasmussen's encephalitis and neuromyelitis optica, 
the latter characterized by antibodies to aquaporin-4 (Whitney et al., 1999; Lucchinetti et 
al., 2002; Waters et al., 2008). Although antibodies from patients with synaptic 
autoimmune encephalitides can fix complement in vitro, biopsies from patient brains do 
not contain complement deposits (Martinez-Hernandez et al., 2011). Also, given the 
minimal gross tissue damage and the near complete recovery of most patients that are 
diagnosed and treated promptly, it is unlikely that complement mediated cell death plays 
a major role in clinically relevant pathogenesis. 
Antibodies against voltage gated K+ channel associated proteins 
Two overlapping syndromes are associated with proteins that are part of the 
voltage gated K channel complex (Klein et al., 2013). The CNS dominant disease called 
Morvan syndrome is caused by antibodies against the leucine rich glioma activated 1 
protein (LGI1; Lai et al., 2010). It is characterized by limbic encephalitis and autonomic 
dysfunction, but with neuromyotonia less frequently (Liguori et al., 2001). The PNS 
dominant disease, Isaac’s syndrome, is caused by antibodies against contactin-
associated protein-like 2 (CASPR2; Shillito et al., 1995; Lancaster et al., 2011), although 
around half of anti-CASPR2 encephalitis patients also exhibit encephalitis.  
LGI-1 is a secreted protein that has been linked to a pediatric epilepsy disorder 
known as autosomal dominant lateral temporal lobe epilepsy (ADLTE; Nobile et al., 
2009). Animal experiments support the role of normal LGI-1 activity in preventing seizure 
activity; mice with LGI-1 knocked out in pyramidal neurons during embryonic 
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stages exhibited early-onset seizures that were commonly lethal (Boillot et al., 2014). 
LGI-1 when knocked out in rats, mice or zebrafish causes hyperexcitability and seizures 
(Fukata et al., 2010; Teng et al., 2010; Yu et al., 2010).  
There are several known functions of LGI-1, any or all of which could be disrupted 
by the pathogenic anti-LGI-1 antibodies in patients. LGI-1 It integrates into a complex 
with presynaptic voltage-gated potassium channel Kv1.1 and prevents its inactivation by 
blocking the cytoplasmic regulatory protein Kvbeta1 (Schulte et al., 2006). It has also 
been shown to complex with synaptic scaffolding proteins ADAM22 and ADAM23, which 
stabilize and retain AMPARs at the synapse. LGI-1 knockout rats had decreased AMPA 
mEPSP amplitude in the hippocampus of acute brain slices suggesting that LGI-1 
potentiates AMPAR-mediated synaptic transmission (Ohkawa et al., 2013). 
In anti-LGI-1 encephalitis, antibodies result in a loss of AMPARs from glutamatergic 
synapses. The antibodies disrupt LGI-1 and ADAM22/23 interaction that may destabilize 
the machinery that sequesters AMPARs to synaptic membranes. Soluble extracellular 
ADAM22 mimicked the effect of anti-LGI-1 antibodies on AMPAR trafficking out of the 
synaptic domain.  This is similar to the disruption of the interaction between NMDARs 
and EphB2Rs by anti-NMDAR antibodies (Mikasova et al., 2012). It would be interesting 
to measure the diffusion coefficient of quantum dot labeled AMPARs after exposing the 
neuron to anti-LGI-1 antibodies. The role of LGI-1 in maintaining AMPAR levels has 
been confirmed in vivo. LGI-1 null mice have reduced AMPARs at synapses.  The 
ADAM22 complex binds to ADAM23 presynaptically and this is thought to regulate levels 
of synaptic AMPAR levels. Changes in AMPAR levels underlie plasticity, global brain 
excitability, and homeostatic scaling that maintains the average synaptic gain while 
preserving the information encoded in the relative strengths of synaptic inputs onto a 
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neuron (Shepherd and Huganir, 2007; Lu et al., 2009; Ohkawa et al., 2013) 
Antibodies against GABA receptors 
Patients with antibodies against either the ionotropic GABAAβ3 subunit or 
metabotropic GABAB receptor B1a subunit typically present with seizures that are 
refractory to antiepileptic treatment. Patients with either disease have a higher risk of 
mortality typically due to unmitigated status epilepticus (Höftberger et al., 2013; Petit-
Pedrol et al., 2014). The patient presentations are consistent with the known functions of 
both ionotropic and metabotropic GABA receptors.  Human mutations in either GABAA or 
GABAB have been associated with genetic epilepsy syndromes.  Mice that are genetic 
nulls for either GABAA subunits or GABAB receptors have a lower seizure threshold 
(Prosser et al., 2001). Important antiepileptic and anxiolytic drugs such as 
benzodiazepines and barbiturates modulate GABAA activity.  Similarly, baclofen, a 
GABAB antagonist, is used as an anti-spasmodic.  
Despite the similarity in presentation and clinical course, the mechanism of 
antibody-mediated disruption of the cognate receptor is different in the anti-GABAA and 
anti-GABAB encephalitis. Similar to the encephalitides with antibodies against 
glutamatergic ionotropic receptors, patient anti-GABAA antibodies reduce both synaptic 
GABAA receptors as seen by immunostaining and picrotoxin sensitive IPSCs in cultured 
hippocampal neurons. The effects of these antibodies are specific for the cognate 
receptors; anti-GABAA antibodies do not affect NMDARs, glutamatergic synaptic 
transmission, or the localization or amount of the GABAA synaptic anchoring protein, 
gephryn.  
In contrast to anti-GABAA receptor antibodies, it is striking that anti-GABAB1 
receptor antibodies do not result in a loss of surface GABAB receptors. How then do anti-
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GABAB antibodies result in a change in inhibitory tone via GABAB activation that is likely 
to underlie the refractory status epilecticus in patients?  In live cultured neurons, 
application of a GABAB agonist such as baclofen results in a reduction in global synaptic 
activity. Anti-GABAB antibodies block this effect. If GABAB1 antibodies do not reduce the 
density of GABAB receptors, then they must inactivate or interfere with the target 
receptors. One possibility is that the antibodies act as an orthosteric or an allosteric 
blocker of GABAB receptors. This would predict that patient antibodies can disrupt 
GABAB signaling with an acute application, and the antibody blocking effect should be 
dose dependent. Additionally, an allosteric agonist of GABAB1 or an activator of GABAB2 
should circumvent the GABAB signaling block by patient antibodies. Another possibility is 
that the patient antibodies activate the GABAB receptors and a prolonged incubation with 
patient antibodies results in a tonic constitutive GABAB signaling, which then results in 
deactivation of receptors. These questions are currently being addressed by studying 
the pharmacological properties of anti-GABAB antibodies in both cultured neurons and 
heterologous cultured cells that have been transfected to express GABAB receptors 
exogenously. 
Homeostatic plasticity in response to antibody-mediated decrease of receptor 
levels 
Homeostatic plasticity is important for maintaining the stability of neuronal network 
activity in the face of potentially destabilizing changes in the strengths of individual 
synapses.  Compensatory mechanisms at the cellular and synaptic level have been 
shown to occur in autoimmune disorders of the nervous system in humans and in 
experimental model systems.  Studies from mouse models of myasthenia gravis and 
patients' tissue have shown an enhanced rate of synthesis of AChRs and increased 
expression levels of AChR α, β, δ, and ε subunits, as well as increased 
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ACh release upon stimulation (Wilson et al., 1983; Guyon et al., 1994, 1998; Plomp et 
al., 1995). Similarly, in the CNS, Purkinje cells treated with IgG from patients with 
Lambert-Eaton syndrome show a loss of P/Q-type voltage gated calcium channel 
currents and a concomitant increase in R-type currents (Pinto et al., 1998). The NMDAR 
hypofunction in anti-NMDAR encephalitis led us to the question of whether patient 
antibody treatment can induce homeostatic changes in cultured neurons.  
It is well known that after pharmacological blockade of glutamate receptors, 
cultured neurons compensate by changing both excitatory and inhibitory synaptic 
strength. Several studies have shown that, after 48 hours of NMDAR or AMPAR 
blockade, mEPSC amplitude is enhanced (Turrigiano et al., 1998; Sutton et al., 2006). 
Treatment of cultured neurons with antibodies from patients with anti-NMDAR 
encephalitis results in a decrease in glutamatergic transmission via NMDA receptors. 
Therefore it is plausible that neurons compensate for a loss of functional NMDA 
receptors by reducing inhibitory synaptic transmission or by increasing NMDAR and 
AMPAR expression. Treatment of cultured neurons does not increase expression of 
NMDARs or AMPARs, but result in a decrease in inhibitory synapse density visualized 
as colocalizing GABAA and VGAT clusters (Moscato et al., 2014).  
Similarly, in anti-AMPAR encephalitis, antibody treated neurons compensate for the 
loss of AMPAR conductance by decreasing GABAAR mIPSC amplitude. In addition to 
changes at the synapse, treatment with anti-AMPAR antibodies increases intrinsic 
neuronal excitability (Peng et al., 2014). While the average action potential firing 
frequency was unaffected, antibody treatment changed the pattern of firing as evidenced 
by a decrease in inter-spike interval. These compensatory changes are consistent with 
numerous observations that pyramidal neurons tend to homeostatically maintain firing 
rate in response to chronic inactivity (Turrigiano et al., 1998; Burrone et al., 
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2002). This may explain why despite reducing excitatory synaptic transmission via 
glutamate receptors, patient antibodies are capable of inducing synaptic and neuronal 
changes that contribute to the short-term memory loss and seizures observed in patients 
with anti-AMPAR encephalitis. 
In vivo effects of anti-receptor antibodies on circuits and behavior 
Patient antibodies disrupt their cognate antigens at synapses in cell culture. This 
synaptic dysfunction and the accompanying homeostatic changes are likely to underlie 
the circuit malfunction and psychologic and neurologic deficits in patients. To test 
whether anti-NMDAR antibodies from patients can disrupt NMDAR-dependent circuit 
properties in vivo, Zhang et al. (2012) tested the effect of a short treatment with patient 
antibodies on LTP induction at Schaffer collateral–CA1 synapses in rodent acute 
hippocampal slices.  Genetic and pharmacological block of NMDAR blocks induction of 
LTP at these synapses although their activity is not necessary for maintenance of LTP.  
In slices treated with anti-NMDAR antibodies for 15 minutes, the induction of LTP by 
theta burst stimulation was suppressed (Fig. 4C-D; Zhang et al., 2012). This suppression 
was not present when slices were treated with patient CSF that had antibodies adsorbed 
on HEK cells overexpressing NMDAR.  LTP in hippocampal synapses is a leading 
candidate for the circuit property that encodes place memory and loss of LTP induction 
in the hippocampus of rodents after exposure to patient antibodies may disrupt memory 
in awake behaving animals. 
 In a large rodent study, Planaguma et al. (2014) generated a passive immune 
transfer model of anti-NMDAR encephalitis to test the effects of patient antibody infusion 
on animal behavior. Using osmotic pumps, they infused a dialyzed mixture of CSF from 
several patients or controls into the cerebral ventricles of mice for 14 days. The pumps 
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were removed after 14 days to enable studying recovery from a chronic exposure to 
pathogenic antibodies from patients.  A dramatic loss of novel object memory and 
anhedonia in the mice with chronic infusion of patient antibodies was observed over 14 
days of infusion. However, by day 18 (day 4 after cessation of infusion), both the 
memory deficits and anhedonia had returned to control levels (Fig. 4E). The behavioral 
deficits correlated with a NMDAR levels in the brain, which also decreased during the 
14-day infusion and recovered completely by day 21 (Planagumà et al., 2014).  This 
study demonstrates the pathogenic potential of antibodies present in patients with anti-
NMDAR encephalitis. It also establishes the relationship between the effects of 
pathogenic antibody on synapse and circuit function, and the changes in behavior, 
memory and cognition that are hallmarks anti-NMDAR encephalitis.   
Recent translational studies have begun to shed light on whole brain activity during 
anti-NMDAR or anti-AMPAR encephalitis. Diffusion tensor MRI in anti-NMDAR patients 
shows decreased functional connectivity between the two hippocampi and extensive 
white matter changes that correlates with disease severity (Finke et al., 2013). Imaging 
studies in anti-AMPAR encephalitis patients have identified hypermetabolism in the 
limbic area on 18-F-FDG PET, which correlates with severity of clinical course (Spatola 
et al., 2014). EEG studies identified a characteristic electrographic pattern in anti-
NMDAR encephalitis known as “extreme delta brush”, characterized by rhythmic delta 
activity at 1-3 Hz with superimposed 20-30 Hz bursts superimposed on each delta wave 
(Schmitt et al., 2012; Armangue et al., 2013). The clinical significance of the extreme 
delta brush pattern is unclear, but reflects widespread cortical and subcortical network 
dysfunction. 
Mechanisms of autoimmunity 
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In the majority of autoimmune encephalitides, patients are much more likely than 
normal to have an associated neoplasm. These encephalitides were initially classified as 
paraneoplastic syndromes. The associated tumors are often dedifferentiated tissues that 
express many neuronal proteins. Among patients with teratomas, the ones with a 
comorbid NMDAR encephalitis were more likely than neurologically intact patients to 
have dysplastic CNS neurons in teratomas that express NMDARs (Day et al., 2014). 
The tumor microenvironment along with the inappropriate expression of neuronal 
proteins in non-neuronal contexts may contribute to the breakdown of immune tolerance 
(Maueröder et al., 2014). Another possibility is that mutant genes in tumors produce 
proteins are structurally different enough from the wild type protein to escape immune 
tolerance and induce an immune response that is cross-reactive to both the mutant and 
wild type gene product (Engelhorn et al., 2006). A well-studied example is scleroderma, 
an autoimmune connective tissue disease, in which a subset of patients that have 
autoantibodies to RNA polymerase III are more likely to have cancer (Shah et al., 2010). 
The cancers in these scleroderma patients harbor missense mutations in the gene 
encoding for RNA polymerase III, POLR3A, and the T cells in these patient that were 
reactive to mutant RNA polymerase cross-reacted with the wild type form of the protein 
(Joseph et al., 2014). 
Not all patients with autoimmune encephalitis have a co-morbid neoplasm. It is 
possible, but unproved, that an immune response elicited by the tumor and the 
subsequent antibody synthesis decreases the size or eliminates the tumor via antibody 
binding and complement mediated cytotoxicity. Thus, at the time of diagnosis, antibodies 
are present, but no tumor is detected. 
 A genetic predisposition to autoimmunity may contribute to sensitizing the immune 
system against essential synaptic proteins. Another evidence for the 
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association between tumor and synaptic autoimmunity is that higher titers correlated with 
poor outcome and presence of teratoma. In the case of anti-NMDAR encephalitis, the 
presence of a tumor is correlated with more severe disease and higher titers. 
Conversely, in patients with tumors, excision of the tumor was one of the most effective 
treatment modality (Gresa-Arribas et al., 2014). 
Identification of the epitope of pathogenic antibodies in anti-NMDA, anti-AMPAR, 
anti-CASPR2 and anti-GABAB1 encephalitides raise an intriguing possibility that regions 
of these synaptic proteins may be inherently immunogenic. In all these diseases, the 
identified epitope is nearly identical regardless of the age, sex, tumor status, or disease 
severity of patients (Gleichman et al., 2012). Moreover, in anti-NMDAR encephalitis, the 
epitope remained constant over disease progression (Gresa-Arribas et al., 2014). 
Domain swapping and point mutation experiments identified the N368/G369 region of 
the LIVBP domain of NMDAR1 to be the minimal epitope necessary for antibody binding 
(Gleichman et al., 2012). 
Molecular mimicry or the cross reactivity of antibodies against infectious epitopes 
with normal host proteins can occur if the epitopes are sufficiently similar.  Guillain-Barré 
syndrome (GBS), an immune mediated peripheral neuropathy affecting axons and 
myelin sheaths is a classic example of an autoimmune neurologic disease that is known 
to arise from molecular mimicry (Hahn, 1998; Hughes and Cornblath, 2005). The 
disorder is frequently preceded by an infection, often by Campylobacter jejuni (Rees et 
al., 1995; McCarthy and Giesecke, 2001). Patients' serum antibodies react with 
peripheral nerve gangliosides as well as lipooligosaccharide from Campylobacter 
jejuni (Oomes et al., 1995; Yuki et al., 2004). Similarly, a syndrome known as 
Sydenham's chorea is characterized by abnormal movements, hypotonia, and 
neuropsychiatric symptoms, and characteristically occurs after an 
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infection by group A streptococci (Marques-Dias et al., 1997; Kirvan et al., 2006). Like in 
GBS, antibodies from patients with Sydenham's chorea react with gangliosides 
expressed in the basal ganglia and cross-react with group A streptococcal N-acetyl-
glucosamine (Bronze and Dale, 1993; Kirvan et al., 2003). Patients with SLE, a 
multisystem autoimmune disease, can harbor antibodies to double stranded DNA that 
also cross react with a single epitope present in the extracellular region of NR2A and 
NR2B of the NMDAR (DeGiorgio et al., 2001; Kowal et al., 2006). Cross reacting anti-
double stranded DNA antibodies are more prevalent in SLE patients with 
neuropsychiatric symptoms, but can also be seen in neurologically normal patients.   
The source and brain access of autoantibodies 
Two different, but not mutually exclusive, sources of pathogenic antibodies can 
synthesis of antibodies within the intrathecal space by plasma cells derived from anti-
neuronal targeted B cells that translated across the blood brain barrier and matured 
within the intrathecal space or the antibodies are synthesized peripherally and cross the 
blood brain barrier that has been pathologically disrupted. 
Antibodies that are synthesized in peripheral lymph nodes and serum can cross the 
blood brain barrier passively and down their concentration gradient if the barrier 
becomes more permeable in disease. There are several methods for experimentally 
increasing BBB permeability to test the effect of peripherally generated antibodies on 
CNS functions including focal ultrasound (Kinoshita et al., 2006), hypertonic solute 
(Neuwelt et al., 1988) and lipopolysaccharide (Xiao and Jan, 2009). More physiologically 
relevant models of BBB disruption include peripheral inflammation (Rabchevsky et al., 
1999; Huber et al., 2001), acute stress (Esposito et al., 2002), and epinephrine (Huerta 
et al., 2006). At least in rodent models, crossing of serum protein including antibodies 
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has been shown to increase after inducing a “leaky” blood brain barrier experimentally. 
Iodinated antibodies injected into rats were detected in the brain following osmotic 
opening of the BBB (Neuwelt et al., 1988). Kinoshita et al. showed that focal sonication 
caused BBB disruption allowing intravenously injected dopamine receptor antibodies to 
enter the brain and bind to antigen at sites of barrier breakdown (Kinoshita et al., 2006). 
A clinical observation that is consistent with the possibility of peripheral antibody 
synthesis with transudation across a disrupted blood brain barrier is that many patients 
with autoimmune encephalitis report a history of flu-like prodromal symptoms or 
demonstrated viral infection prior to presenting with neuropsychiatric syndrome of 
autoimmune encephalitis (Dalmau et al., 2004). It is possible that a systemic 
inflammation induced by a bacterial or viral infection transiently disrupts the BBB, and 
allows antibodies that were already present in the serum to enter the intrathecal space. 
Memory B-cells that are able to cross a normal BBB will undergo re-stimulation, 
antigen-driven affinity maturation, clonal expansion, and differentiation into NMDAR 
antibody-secreting plasma cells. This mechanism, which occurs in other autoimmune 
diseases such as multiple sclerosis (Hauser et al., 2008), would explain the detection of 
intrathecal synthesis of antibodies in most patients with anti-NMDAR encephalitis. 
Clinical pathology investigations of CSF from autoimmune encephalitis patients support 
intrathecal synthesis of pathogenic antibodies. These patients often have an increased 
ratio of CSF IgG to serum IgG concentration. This could result from the intrathecal space 
being the source of antibodies and the peripheral space being the sink or anti-neuronal 
antibodies present in serum when given access to neuronal tissue get sequestered close 
to the neuronal tissue. Additionally, protein electrophoretic analyses of the CSF from 
autoimmune encephalitis patients demonstrates multiple distinct bands of IgG that are 
absent in serum (oligoclonal bands), supporting the presence of plasma cell 
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clones within the thecal space that that are absent in serum and thus may have matured 
after their progenitor B cells extravasated intrathecally (Dalmau et al., 2008). 
The relative lack of efficacy of strategies for treating autoimmune encephalitis by 
depleting serum IgG (IVIg, plasma exchange) is another piece of evidence to support the 
presence of the source of pathogenic antibodies intrathecally. IVIg and plasmapharesis 
alone are no longer considered standard of care or appropriate first line treatment for 
autoimmune encephalitis (Martinez-Hernandez et al., 2011). Patients that do not 
respond to IVIg or plasma exchange often improve with immunomodulatory drugs that 
affect immune cells such cyclophosphamide and rituximab. Also, a retrospective study of 
titers and disease progression showed that higher titers of antibodies in CSF but not in 
serum correlated with poor neurologic outcome (Gresa-Arribas et al., 2014). Additionally, 
relapses of neuropsychiatric decline correlated more with CSF titer change than serum 
titer.  
There is also direct evidence for the presence of CD138+ plasma cells in 
perivascular, interstitial and Virchow-Robin spaces in brain biopsies from patients (Fig. 
5). Biopsies in 14 cases and autopsy of three patients showed microgliosis, occasional 
inflammatory B-cell and plasma cell infiltrates, and very rare T-cell infiltrates (Martinez-
Hernandez et al., 2011), in contrast to other paraneoplastic syndromes in which only 
cytotoxic T-cell infiltrates are prominent (Stein-Wexler et al., 2005).  These lymphocytes 
may be recruited by chemokines secreted by monocytes and microglia. Patients have a 
higher level of B-cell–attracting C-X-C motif chemokine 13 (CXCL13) in their CSF 
compared to controls but there was no difference in serum (Leypoldt et al., 2014). 
Moreover, anti-NMDAR patients from whom brain biopsy samples are available showed 
infiltration of monocytes and microglia that express CXCL13 (Fig. 5C). This suggests 
that despite being an immune privileged organ, the intrathecal space 
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of autoimmune encephalitis patients displays all the hallmarks of an organ with an 
adaptive immune system response: antigen presenting cells secreting chemokines, 
extravasation of immature lymphocytes, and mature plasma cells producing anti-
neuronal antibodies. 
Effects of synaptic receptor antibodies related to neurologic symptoms 
Glutamate binding to NMDARs and AMPARs is crucial for synaptic transmission 
and plasticity. Pharmacological blockade or genetic reduction of NMDARs or AMPARs 
has been shown to alter measures of learning and memory and other behaviors in 
animal models (Mohn et al., 1999; Kapur and Seeman, 2002; Schmitt et al., 2007; Labrie 
et al., 2008).  The balance between excitatory and inhibitory synaptic inputs is also 
altered, and this has been shown to affect circuit function and behavior (Prange et al., 
2004; Epsztein et al., 2006; Kehrer et al., 2008). In addition, NMDA (Olney et al., 1999; 
Coyle and Tsai, 2003; Stahl, 2007) and/or AMPA (Wiedholz et al., 2008; Zavitsanou et 
al., 2008) receptor hypofunction has been proposed to be part of the pathophysiological 
mechanisms underlying schizophrenia.    
It is interesting to consider why patients with anti-NMDAR antibodies develop a 
complex syndrome that includes psychosis, learning and memory dysfunction, abnormal 
movements, autonomic instability and frequent hypoventilation, while those with AMPAR 
antibodies preferentially develop psychiatric and amnestic symptoms.  Studies using 
genetic deletion of NMDAR or AMPAR subunits in mouse models provide some insight 
into this issue. While NR1 knockout mice die shortly after birth due hypoventilation (Li et 
al., 1994), mice with spatially restricted NR1 deletion can survive into adulthood 
(Nakazawa et al., 2004). CA1-specific NR1 knockouts have impaired spatial and 
temporal memory and a loss of CA1 LTP (Tsien et al., 1996). Mice with an inducible, 
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reversible knockout of NR1 in forebrain show impairment in the maintenance of long-
term memory if NR1 expression is turned off during the memory storage phase. 
In addition to memory deficits, targeted manipulation of NR1 expression can result 
in schizophrenia-like symptoms. Hypomorphic expression of NR1 leads to increased 
stereotypic behavior and decreased sociability, while early postnatal loss of NR1 in a 
subset of cortical and hippocampal interneurons results in decreased pre-pulse inhibition 
and increased social isolation-induced anxiety (Mohn et al., 1999; Belforte et al., 2010). 
Moreover, subanesthetic doses of NMDAR blockers such as phencyclidine and 
ketamine are psychotomimetic, and they recapitulate many of the positive and negative 
signs of schizophrenia in humans and rodents as well as repetitive orofacial movements, 
autonomic instability and seizures (Luby et al., 1962; Krystal et al., 1994; Lahti, 2001; 
Krystal, 2002).The remarkable similarity between these phenotypes, the effect of 
patients' antibodies resulting in a dramatic decrease of synaptic NMDAR clusters and 
function, and the reduced levels of NMDARs in autopsied patients, support an antibody-
mediated pathogenesis of anti-NMDAR encephalitis, and strengthen the NMDAR 
hypofunction hypothesis of schizophrenia (Belforte et al., 2010). 
The consequences of loss of AMPAR expression have also been studied in mouse 
models. Spatial learning and memory are largely unaffected in GluR1 knockout mice 
despite the fact that LTP is reduced in CA1 and CA3 (Zamanillo, 1999) and working 
memory is diminished (Reisel et al., 2002; Sanderson et al., 2007). GluR2 knockout 
mice show reduced exploration and impaired motor coordination. In these animals, 
AMPAR mediated synaptic transmission is reduced, but LTP is enhanced (Jia et al., 
1996; Gerlai et al., 1998). GluR2 knockout mice also have increased cell death 
(Feldmeyer et al., 1999; Oguro et al., 1999), possibly due to excitotoxicity related to 
increased, compensatory insertion of GluR1 homomeric AMPARs.  While 
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AMPAR subunit knockout mice have not provided a satisfying explanation for the role of 
AMPARs in synaptic plasticity related to learning and memory, the fact that patients with 
AMPAR antibodies have short-term learning and memory deficits argues that further 
studies at the circuit and behavioral levels are warranted. 
GABAB1 receptor knockout mice display a variety of neurologic and behavioral 
abnormalities, including spontaneous seizures, enhanced anxiety, hyperactivity, 
hyperalgesia, and impaired memory (Prosser et al., 2001) suggesting dysfunction of the 
limbic system. Consistent with these experimental data, patients with anti-
GABAB1 receptor antibodies present with an encephalitis that associates with early and 
prominent seizures, confusion, agitation, behavioral problems and severe short-term 
memory deficit along with MRI abnormalities predominantly involving the hippocampi. 
Interestingly, both GABAB1 receptor knock out mice and mice treated with a 
GABAB1 receptor antagonist, CGP56423A, exhibit antidepressant-like behavior in a 
forced swim test and a learned helplessness paradigm (Nakagawa et al., 1999; 
Mombereau et al., 2004), suggesting that GABA signaling may have disparate effects on 
different aspects of mood such as depression and anxiety. Combined with animal 
studies, these patients can provide rich insight into the role of GABAB1 receptor signaling 
in memory, behavior, and cognition. 
Conclusion 
Each of the clinical syndromes under the umbrella of autoimmune encephalitis is an 
opportunity to not only understand the mechanism by which the human body fails to 
distinguish self from non-self but also how autoantibodies cause CNS disease.  The 
basic science and translational work on the unique aspects on each of the autoimmune 
encephalitides underscores the fact that despite a failure in immunotolerance, cellular 
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and humoral factors can disrupt their target antigen in distinct ways.  
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Figures 
 
Fig 1. Flowchart of identifying a cluster of autoimmune encephalitis patients, identifying 
the target antigen, and laboratory characterization. 
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Figure 2.  Process of characterization, antigen immunoprecipitation, and development of 
diagnostic tools. (A) Immunohistochemistry of rat brain section stained with patient CSF 
(anti-NMDA receptor encephalitis; Dalmau et al., 2007). Scale bar = 1mm.  (B) 
Dissociated rat hippocampal neurons maintained in vitro and incubated (live, 
nonpermeabilized) with patient CSF.  Note the binding of of patient's antibodies with 
clusters of cell surface antigens; scale bar = 10 μm. (C) Precipitation of these antigens 
using two patients’ CSF antibodies is shown in a gel in which proteins are visualized with 
EZBlue. Note that patients’ antibodies (P1, P2) precipitated a single band at ∼100 kDa; 
this band is not seen in the precipitate generated with CSF from a control individual (N). 
Analysis of the 100 kDa band by mass spectrometry demonstrated sequences derived 
from GluR1/GluR2 subunits of the AMPA receptor. The ∼50 kDa band across all 
samples corresponds to IgG. Transfer of the proteins to nitro‐cellulose and Western blot 
with GluR1 and GluR2 antibodies confirmed that the 100 kDa band contained both 
GluR1 and GluR2 subunits (not shown). (D-F) Further validation of the antigen was done 
in heterologous cells expressing GluR1/2, showing reactivity with patient's antibodies (D, 
green), a commercial monoclonal GluR1 antibody (E, red), and merged (F, yellow). 
Scale bar = 10 um.  Figure panels from Lai et al., 2009. 
 
 
 
 
  
 
29  
 
30 
Figure 3. Synaptic effects of antibodies from patients with anti-NMDAR encephalitis. (A–
C) AMPA and NMDA receptors are localized in the postsynaptic membrane and are 
clustered at the postsynaptic density.  (A) Patient antibodies bind selectively to synaptic 
and extrasynaptic NMDA receptors, and this binding leads to receptor cross-linking (B). 
Cross-linked and clustered NMDA receptors are internalized, resulting in a decrease of 
surface NMDA receptors while other synaptic components, such as postsynaptic AMPA 
receptor clusters and PSD-95, as well as presynaptic terminals, dendrite branches, 
dendritic spines and cell viability, are unaffected (C).  Panels A-C adapted from Moscato 
et al 2010.  (D–E) Rodent cultured neurons treated within patient's CSF results in 
internalization of antibody bound NMDA receptors. After treatment with patient CSF for 
1h (D) or 12h (E), surface NMDA receptors were stained using an anti-human IgG 
secondary antibody conjugated to Alexa 488 on live cultured neurons.  After fixing and 
permeabalization, an anti-human IgG secondary antibody conjugated to Alexa 594 is 
used to stain the internalized antibody bound fraction of NMDA receptors. 
Counterstaining with a commercial antibody labeled the total pool of NMDA receptors.  
Scale bar = 1 um.  (F–G) Whole-cell patch recordings of miniature excitatory 
postsynaptic currents (mEPSCs) that consist of a fast AMPA receptor–mediated 
component and a slower later component mediated by NMDA receptors that is APV 
sensitive. Compared with neurons without patient antibody mediated internalization, 
those treated with CSF from a patient with NMDA receptor antibodies show a loss of the 
APV-sensitive NMDA receptor component G (Hughes et al., 2010). (H)  Quantification of 
surface and internalized NMDARs following treatment. Surface NMDAR density was 
significantly decreased after 12 hours of patient CSF treatment compared with patient 
antibody-derived F(ab) fragments after which surface levels reached a plateau. This was 
paralleled by an increase over time in the density of internalized NMDARs.  
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Panels D-H adapted from Moscato et al., 2014. 
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Figure 4. Infusion of CSF from patients with NMDAR antibodies into rodent brains 
reduces synaptic NMDA receptors and results in deficits circuit plasticity, memory and 
behavior  (A-B) Three-dimensional projection and analysis of the density synaptic 
clusters of NMDA receptors (defined as NMDAR clusters colocalized with PSD95) in 
CA3 region of hippocampus.  (C-D) Suppression of LTP by CSF obtained from an anti-
NMDAR encephalitis patient (Zhang et al., 2011).  (C) Superimposed field EPSPs 
(fEPSPs) recorded at Schaffer colateral-CA1 synapses immediately before (black) and 
30 min after TBS (red). For assessment of the magnitude of LTP, the initial slope of 
post-tetanic fEPSP (red) was expressed as percent of the pre-tetanic slope (black). The 
slope was measured as indicated in the middle panel (dotted lines). Scale bars: 2 ms 
and 0.5 mV.  (D) Averaged LTP time course. The slope of fEPSPs was expressed as 
percent of those recorded immediately before TBS. The lines represent data from the 
artificial CSF control (solid line with filled circles), the non-encephalitis control (solid line 
with open circles), the herpes simplex virus encephalitis control (HSV; chain line with 
open triangles) and the NMDAR antibody positive case (chain line with filled triangles).  
(E) Infusion of CSF from patients with NMDAR antibodies causes deficits in memory, 
anhedonia and depressive-like behavior.  Novel object recognition index in open field is 
reduced in animals treated with patients’ CSF (grey circles) but not control CSF (white 
circles) after 14 days of chronic infusion. The patient CSF infused animals recover their 
novel object memory 11 days after the cessation of infusion (day 25 post surgery).  A 
higher novel object Index indicates better object recognition memory.  Figure adapted 
from Planaguma et al., 2014 and Zhang et al., 2011. 
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Figure 5. Brain biopsy of a patient with anti-NMDAR encephalitis showing perivascular 
lymphocytic and monocytic Infiltrates. (A) In Virchow-Robin spaces, CD138+ plasma 
cells are in perivascular regions (arrows) and along the tissue surface (arrowheads) that 
delineates spaces containing CSF and small vessels (v). The plasma cells/plasmablasts 
indicated with arrows are amplified in the inset in K. Scale bars = 20 m. (B-C) Monocytic 
infiltrates expressing CXCL13, a B-cell attracting chemokine (B, arrow heads).  Infiltrates 
were mainly composed of monocytes and macrophages (B, arrow heads indicate CD68 
expressing monocytes and macrophages). Scale bar = 14 μm.  Figure adapted from 
Stein-Wexler et al., 2005 and Leypoldt et al., 2014. 
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Abstract 
Patients with antibodies to the metabotropic gamma-aminobutyric acid receptor 
type B (GABAB) develop severe intractable seizures, but little is known about the 
underlying pathophysiological mechanisms.  Using deletion mapping and expression in 
heterologous cells, we show that patient anti-GABAB receptor antibodies bind to 
alternatively spliced Sushi domains that is present in the presynaptically localized 
GABAB1a isoform.  In contrast to anti-NMDAR antibodies from patients, GABAB  receptors 
autoantibodies did not decrease in surface GABABRs or their internalization.  Treating 
neurons with GABAB receptors autoantibodies for as little as 30 minutes blocked the 
activation of GABAB receptors by baclofen in an autoantibody titer-dependent manner. 
Autoantibody-bound GABABRs are still signaling competent, however, because baclofen 
block was circumvented by directly activating GABAB2 with a selective agonist, 
CGP7930.  Thus, patient GABAB receptor autoantibodies are selective GABAB1 
antagonists that may contribute to seizures by interfering with GABA-mediated inhibition. 
Brain penetrant GABAB2 agonists may be useful to treat intractable seizures in anti-
GABABR encephalitis patients. 
Introduction  
A growing family of autoimmune neurological diseases defined by pathogenic 
antibodies to neuronal cell surface proteins has been recognized over the last decade 
(Leypoldt et al., 2014). These diseases typically cause profound neuropsychiatric 
disability, and may be fatal (Vitaliani et al., 2005; Dalmau et al., 2008; Finke et al., 2012; 
Petit-Pedrol et al., 2014), but most patients improve markedly with immunosuppression, 
and many patients recover (Iadisernia et al., 2012; Gresa-Arribas 
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et al., 2014). Some of these disorders target important synaptic proteins including the 
ionotropic glutamate receptors, N-Methyl D-Aspartate receptor (NMDAR, Sansing et al., 
2007; Dalmau et al., 2008) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPAR, Lai et al., 2009), the glycine receptor, the ionotropic gamma-
aminobutyric acid receptor type A (GABAAR, Petit-Pedrol et al., 2014) and the 
metabotropic gamma-aminobutyric acid receptor type B receptor (GABABR, Lancaster et 
al., 2010). The neuropsychiatric manifestations of these autoimmune encephalitides are 
similar to those caused by the genetic or pharmacologic disruption of the corresponding 
receptors in animal models and in human genetic diseases (Prosser et al., 2001; Brown 
et al., 2003). The specificity of the autoantibodies for receptor subunits, and often 
dominant epitopes of these proteins, is exquisite (Gleichman et al., 2012, 2014).  While 
studies of the effects of patient antibodies on neurons, synapses, circuits, and behavior 
have begun to provide important insights into the pathophysiologic etiology of patient 
symptoms, many questions remain.  
The cellular effects mediated by NMDAR and AMPAR antibodies have been 
studied in detail (Lai et al., 2009; Hughes et al., 2010; Moscato et al., 2014; Peng et al., 
2014). These antibodies do not directly inhibit receptor function. Rather, NMDAR and 
AMPAR autoantibodies cross-link the cognate synaptic receptors on the surface of 
cultured neurons and result in a selective internalization of the target without disrupting 
other synaptic components or injurying neurons (Hughes et al., 2010; Moscato et al., 
2010; Peng et al., 2014). Chronic perfusion of NMDAR antibodies into the cerebrospinal 
fluid (CSF) of rodents also decreases NMDA receptors after 14 days (Planagumà et al., 
2014). This passive transfer of autoimmunity in mice results in anhedonia and 
diminished spatial memory.  These effects are reversible in both in vivo and in vitro 
model systems (Moscato et al., 2010; Planagumà et al., 2014). Thus, these 
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mechanisms may underlie the neurological and psychiatric manifestations of these forms 
of autoimmune encephalitis, and account for recovery of many patients with immune 
therapy aimed at lowering antibody titer. 
Antibodies to the extracellular domain of B1 subunit of the metabotropic GABAB 
receptor (GABAB1) have been have been identified in a subset of patients with 
autoimmune limbic encephalitis (15, 10, and 20 patients in Lancaster et al., 2010; 
Höftberger et al., 2013; Dogan Onugoren et al., 2014, respectively). These patients 
typically present with subacute seizures that are resistant to treatment, along with 
confusion, memory loss and behavioral problems. Nearly half the patients have a co-
morbid small cell lung cancer, and many patients improve with immunosuppression. 
Other reports have confirmed this association of antibodies to GABAB1 with encephalitis, 
severe seizures, and small cell lung cancers (Lancaster et al., 2010). GABAB1 may be 
the most common antigen in patients with small cell lung cancer and autoimmune 
encephalitis.  
GABAB receptors are G-protein coupled receptors (GPCRs) for the inhibitory 
neurotransmitter GABA (Kaupmann et al., 1997).  They are obligate heterodimers of 
GABAB1, which binds GABA, and GABAB2, which activates intracellular G-protein 
mediated signaling (Robbins et al., 2001; Schwenk et al., 2010).  The GABAB1 subunit 
has two distinct isoforms with different localization and function (Vigot et al., 2006).  
GABAB1a is found in presynaptic receptors, which can decrease in synaptic vesicle 
release by inhibition of presynaptic calcium influx (Harrison, 1990). The GABAB1b 
subunit is found in post-synaptic receptors (Hannan et al., 2012), which can reduce 
excitability by the opening of G-protein coupled inwardly rectifying K+ channels (GIRK, 
Lüscher et al., 1997).  Hypoactivity of GABAB signaling is implicated in epilepsy, 
spasticity, anxiety, addiction, autism and pain.  GABAB1 null mice have 
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decreased sensorimotor gating, spontaneous seizures, hyperlocomotion and memory 
impairment (Prosser et al., 2001).  Baclofen, a selective GABAB agonist, is used 
routinely to treat spasticity in patients.  
Here, we describe the target epitope of human GABAB1 autoantibodies and 
demonstrate that these antibodies preferentially target the GABAB1a isoform of the 
receptor.  The cellular effects of anti-GABAB1a antibodies on cultured hippocampal 
neurons are strikingly different from those of antibodies to ionotropic glutamate 
receptors. GABAB1 antibodies do not result in internalization of surface GABAB 
receptors.  Rather, patient GABAB1 antibodies prevent activation of the GABAB1 subunit 
by the agonist baclofen, without affecting the ability of the GABAB2 subunit to induce G-
protein mediated signaling.  GABAB1 receptor antagonism may account for the severe 
and intractable seizures that are prominent in patients with CSF GABAB1 antibodies.  
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Materials and Methods 
Patients and human samples 
Cerebrospinal fluid and serum were obtained from patients with well-characterized 
clinical manifestations of anti-GABAB receptor encephalitis. Control samples were 
obtained from patients undergoing CSF screening for various disorders not associated 
with antibodies against known neuronal antigens.  Control CSF used in this study was 
confirmed to not have any anti-neuronal antibodies using the methods described below. 
The clinical characteristics of patients with GABAB antibodies whose CSF was used in 
this study have been described previously (Lancaster et al., 2010; Höftberger et al., 
2013).  
Primary neuron cell culture and treatment  
Hippocampi from embryonic day 18 rat pups were subjected to proteolytic digestion 
and mechanical disruption as previously described (Hughes et al., 2010). Briefly, 
dissociated cells were plated onto poly-L-lysine coated 15 mm coverslips at a density of 
25,000 cells/cm2 and incubated in Neurobasal medium.  Neurons were treated on days 
in vitro (div) 17 – 21 with CSF from patients or controls at dilutions specified in the figure 
legends. 
Antibodies  
The following antibodies were used at the indicated dilutions for Western blots 
(WB), HEK293 cells (H) or dissociated neurons (N): GluN1 (rabbit, WB 1:1000, Millipore 
AB9864R), GluA1 (rabbit, WB 1:200, Millipore AB1504), GABAB1Rs (guinea pig, WB 
1:200 N 1:500 H 1:2000, Millipore AB2256), GABAARβ2/3 (mouse, WB 1:200, Millipore 
05-474), and β-actin (chicken, WB 1:1000, Abcam ab13822), myc tag (mouse, 1:1000, 
Sigma 9E10). Omission of primary antibodies was used as a control for each of the 
secondary antibodies, which were raised in goat and conjugated to 
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various Alexa Fluor or Dylight dyes (Jackson Immunoresearch). 
Immunostaining and microscopy 
Hippocampal neurons on coverslips were fixed and stained as previously described 
(Hughes et al., 2010).  Briefly, neurons were fixed with freshly prepared 4% 
paraformaldehyde/4% sucrose for 10 min, blocked in 5% goat normal serum/ 0.1% 
Triton X-100 for 1 hour and washed in phosphate buffered saline (PBS) three times for 5 
min each, incubated with primary antibodies diluted in block overnight at 4oC and 
washed, then incubated in secondary antibodies for 1-2 hours at room temperature and 
washed.  Coverslips were mounted, sealed and imaged on a confocal microscope (TCS 
SP5, Leica, Wetzlar, Germany).   
To selectively label internalized human IgG, neurons were incubated with patient 
CSF (1:50), followed by incubation with goat anti-human secondary antibody conjugated 
to Alexa 488 (1:100).  After 1-2 hours, neurons were fixed, permeabalized, and stained 
with goat anti-human secondary antibody conjugated to Alexa 594 to selectively label 
human IgG bound internalized receptors. 
Images acquired on the confocal microscope were analyzed using custom-written 
ImageJ macros as previously described (Hughes et al., 2010). Briefly, images were 
background corrected by subtracting a Gaussian blur of the image, followed by adaptive 
thresholding and cluster detection to produce a binary mask of clusters (Bergsman et al., 
2006). 
Immunohistochemical staining of brain sections was carried out as described 
previously (Gable et al., 2009). Briefly, mouse brain hemisections were immersion fixed 
in freshly prepared 4% paraformaldehyde for 2 hours and then cryoprotected in 30% 
sucrose until equilibrated. Snap frozen brains were saggitally sectioned at 10 um, and 
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mounted on glass slides. Sections were immersed in 0.3% hydrogen peroxide for 10 min 
and then washed, blocked in 5% goat normal serum, incubated with patient CSF (1:50) 
overnight at 4oC and washed, then incubated with biotinylated goat anti-human IgG 
secondary antibody (1:2000) and washed, incubated with avidin-biotin-peroxidase 
complex (ABC kit, Vector Labs) for 1 hour and washed. The sections were incubated 
with diaminobenzidine (DAB Eqv, Vector Labs) for 5 - 15 mins; the reaction was stopped 
when a section not incubated with patient CSF begins developing staining. The sections 
were washed, counterstained with hematoxylin, dehydrated in ethanol, cleared in 
Citrasolv (Fisher) and mounted with Permount (Sigma). 
Biotinylation of surface proteins and analysis by Western blot  
Five coverslips of dissociated hippocampal neurons were treated with patient or 
control CSF (1:25) for 24 hours and prepared for protein extraction as previously 
described (Hughes et al., 2010).  Briefly, neurons were washed in PBS, incubated with 
1mg/ml sulfo-NHS-biotin (Thermo Fisher Scientific) for 30 min at 4oC, lysed in RIPA 
buffer (150 mM NaCl, 1 mM EDTA, 100 mM Tris-HCl, 1% Triton X-100, 1% sodium 
deoxycholate, 0.1% SDS, pH 7.4, supplemented with 1:500 protease inhibitor mixture III 
(Calbiochem) for 1 h at 4°C, and centrifuged at 4000g for 20 minutes.  An aliquot of the 
supernatant was assayed for total protein. The biotinylated fraction of proteins in the 
remaining supernatant was adsorbed onto avidin-linked agarose beads (Immobilized 
Monomeric Avidin; Thermo Fisher Scientific) overnight at 4°C, beads precipitated, and 
the supernatant was saved to assay proteins in the intracellular fraction.  Protein bound 
to beads was eluted to assay proteins in the surface fraction. Protein samples were 
denatured and reduced by boiling in Laemmli buffer, separated on a 4-15% gradient 
SDS-PAGE gel and transferred to nitrocellulose membranes. The surface, intracellular 
and total fractions were probed with primary antibodies. Membranes were 
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incubated with alkaline phosphatase (AP)-conjugated goat secondary antibodies 
(1:3000, Cell Signaling), and signals were visualized using Western-Star 
chemiluminescent detection system (Applied Biosystems). 
Heterologous cell transfections and cDNA constructs 
GABAB1a and GABAB2 cDNAs were the gift of Dr. Steve Moss (Calver et al., 
2000).  mCD8 cDNA was a generous gift from Dr. Steve Scherer. All deletion constructs 
were generated with the Quickchange kit following a modification of the manufacturer’s 
protocol.  
HEK293 cells (ATCC) were grown on Poly-D-lysine coated coverslips in 24 well 
plates in DMEM supplemented with 5% fetal bovine serum, 5% horse serum, glutamine 
and penicillin/streptomycin cocktail. At log phase of growth (60-80% confluency), the 
media was exchanged for 400 µL of serum-free media (OptiMEM, Invitrogen). For each 
well, transfection was carried out with a total of 1 µg of plasmid DNA premixed and 
preincubated with 3 µL of Lipofectamine LTX (Invitrogen) in 100 µL of OptiMEM. Twenty 
four hours after transfection, HEK 293 cells were fixed in 4% paraformaldehyde for 10 
minutes, fixed in 5% goat normal serum for one hour and either used immediately for 
immunocytochemistry or frozen at -80oC for later use.  
Electrophysiological assays 
Whole cell current clamp and voltage clamp measurements were recorded from div 
17-21 neurons that had been treated with patient or control CSF for the duration 
specified. Extracellular solution was perfused at 1 ml/min and was composed of (in mM): 
140 NaCl, 3 KCl, 2.5 CaCl2, 0.6 MgCl2, 30 glucose, 10 HEPES, pH titrated to 7.4 with 
10N NaOH. Patch pipette electrodes were prepared from borosilicate glass with 
resistance within 4-8 MΩ. The composition of intracellular solution was (in mM): 140 
Kgluconate, 2 MgCl2, 10 HEPES, 11 EGTA, 7 glucose, 2 ATP, 0.3 GTP, pH 
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7.3.  The pharmacological agents used were racemic baclofen (1 mM in water, pH 7.4 
with NaOH, Tocris) and CGP7930 (10 mM in DMSO, Tocris) at the indicated 
concentrations. Before a gigaOhm seal was formed on neurons, voltage offset was 
compensated. Membrane resistance, series resistance, and membrane capacitance 
were determined from current transients elicited by a 5 mV depolarizing step from a 
holding potential of -80 mV before switching to current clamp mode with a command 
current of 0 mA.  Membrane potential was amplified and low pass filtered with a 5 KHz 
cutoff Bessel filter before being sampled and digitized at 10 KHz. Firing rate was 
determined offline using StimFit (Schlögl et al., 2013). Action potential recordings were 
acquired in current clamp mode.  Action potentials were detected by counting threshold 
crossing of the first time derivative of the membrane potential trace.  
Statistical Analysis 
Data that passed tests for normality by the D’Agostino and Pearson test were 
analyzed with parametric tests, specifically t test for one factor with two levels, one-way 
ANOVA for multi-level experiments and two-way ANOVA for two factor experiments. 
Post-hoc testing for group differences in parametric tests was one using the Dunn test. 
In experiments where the sample statistic had a theoretical maximum or a minimum and 
deviated from normality were tested using non-parametric Kruskal-Wallis test with the 
Holm-Sidak post-hoc test for group differences. 
Analysis of antagonism by patient CSF was done using Gaddum/Schild EC50 shift 
analysis by parametric nonlinear fitting in GraphPad Prism. The firing rate in the 
presence of GABAB ligands was converted to efficacy in percent. Firing rate that was 
identical to baseline was set as 0% efficacy while a firing rate of 0Hz i.e. maximal 
inhibition in the presence of drug was set as 100% efficacy. pA2, B and Schild slope 
were shared parameters between CSF concentration or duration of CSF 
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incubation but, the Hill slope parameter was unconstrained.  
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Results 
Patient CSF contains antibodies that bind to GABAB1 receptors  
CSF samples from 10 patients with GABAB antibodies whose clinical characteristics 
were described previously (Lancaster et al., 2010; Höftberger et al., 2013) were used in 
these studies.  We determined that all patients whose CSF was used in this study had 
anti-GABAB immunoglobulins by immunostaining unfixed, unpermeabilized cultured rat 
hippocampal neurons.  Confocal microscopy confirmed that 10/10 patient CSF samples 
labeled clusters on the surface of cell bodies and processes (N = 3 replicates, 2-3 
coverslips each, 4 neurons/coverslip).  Whether these clusters contained GABAB1 
receptors was determined by analyzing images from neurons that were subsequently 
fixed, permeabalized and labeled with a commercial antibody to an intracellular GABAB1 
receptor epitope.  Nearly all (85  7%; N = 1 replicate, 3-8 coverslips each, 4 
neurons/coverslip) human IgG-bound surface clusters were also labeled with the 
GABAB1 antibody (Fig. 1B) overlapped with a subset of clusters (41  15%) recognized 
by a commercial antibody to an intracellular epitope on GABAB1 receptor (Fig. 1B).  This 
confirms that the immunoglobulins in patient CSF recognize the GABAB1 receptor 
subunit (Lancaster et al., 2010). 
To verify that patient CSF autoantibodies bind directly to GABAB1 receptors and not 
to other proteins that colocalize with GABAB1, HEK293 cells were transfected with cDNA 
constructs encoding GABAB1a and GABAB2 receptors and immunostained with patient 
CSF and/or commercial GABAB1 receptor antibodies.  Cells that expressed GABAB1 
were identified after immunostaining with commercial GABAB1 antibodies (N = 2-10 
replicates, 2-5 coverslips each).  All cells that expressed GABAB1 also bound human IgG 
from the CSF of the 10 patients used (Fig. 1C).  
While CSF from patients contains antibodies to GABAB1 
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receptors, it is possible that some of the neuronal reactivity with CSF could be explained 
by antibodies to other neuronal proteins. To evaluate this possibility, we immunostained 
sagittal brain sections from Gabbr1-null mice and wild-type littermates with CSF from 
patients and controls (Fig. 1D). All three patient CSFs tested, but not three control CSFs, 
strongly stained hippocampus, thalamus and striatum in wild-type brain sections in a 
pattern similar to their staining of wild-type rat brains (Lancaster et al., 2010). In contrast, 
neither patient CSF nor control CSF stained Gabbr1-null brain sections (Fig. 1D).  These 
results suggest that the patient CSFs tested contain antibodies only to GABAB1 receptor 
subunit. 
Taken together, these results confirm that patients with anti-GABAB1 receptor 
encephalitis have immunoglobulins in their CSF that bind to GABAB1 receptors and that 
this binding accounts for the reactivity of their CSF with brain tissues. 
Patient antibodies bind to GABAB1a receptor Sushi domains 
Antibodies in patient CSF bind to an extracellular region of the GABAB1 receptor 
subunit, as evidenced by surface staining of unfixed, unpermeabilized neurons (Fig. 1; 
Lancaster et al., 2010).  GABAB1 is comprised of a large N-terminal extracellular domain 
(NTD) that is linked to the seven transmembrane domain typical for the GPCR 
superfamily.  The only extracellular epitopes of GABAB1 are the NTD and the linkers 
between transmembrane helices 2-3, 4-5, and 6-7.  To determine the minimal GABAB1 
epitope required for patient antibody binding, cDNAs encoding GABAB1 receptors with 
different deletions (Fig. 2A) were expressed in HEK cells, followed by immunostaining 
with patient CSF. 
When the NTD was deleted, 10/10 patient CSFs tested (N = 4 replicates, 6-10 
coverslips, 100-200 cells) no longer bound to HEK293 cells expressing GABAB1NTD 
 
67 
(Fig. 2B). These results demonstrate that the NTD is necessary for autoantibody binding. 
The NTD in GABAB1a has two subdomains, the ligand-binding Venus Flytrap 
Domain (VFT) and the alternatively spliced doublet of Sushi domains (SD) at the amino-
terminus (Fig. 2A). All (7/7) patient CSFs tested bound to HEK cells transfected with the 
construct lacking the VFT domain (VFT) (Fig. 2C; N = 3 replicates, 3 coverslips, 100-
200 cells).  This result shows that the VFT is not the immunodominant domain of 
GABAB1.  
Since the majority of the residues in the NTD make up the VFT, we next assessed 
the smaller SDs and short inter-domain loops as potential immunodominant domains. 
When SDs were deleted from GABAB1a, 3/3 patient CSFs tested no longer bound to 
transfected HEK cells (Fig. 2D; N = 2 replicates, 1 coverslip, 100 cells). This result 
indicates that the SDs is necessary for autoantibody binding.  
It is possible that deleting GABAB1 domains interfered with the correct folding of the 
remaining tertiary structure. Even if a misfolded protein remnant contained the epitope, it 
might fail to bind antibodies. To further confirm that the immunodominant epitope is 
within the SD, and the loss of autoantibody staining in the ∆SD construct was not due to 
a misfolded or otherwise blocked epitope on the remaining protein, the SD was fused to 
a membrane carrier derived from mouse CD8 receptors (NTD::CD8). HEK cells 
transfected with the NTD::CD8 fusion construct bound human autoantibodies from 3/3 
patient CSFs (Fig 2E; N = 2 replicates, 2 coverslips; 100 cells).  
Taken together, these data show that the alternatively spliced SDs in GABAB1a are 
necessary and sufficient for antibody binding.  
Patient CSF antibodies do not reduce surface receptor cluster density 
Previous work has shown that divalent antibodies in CSF from patients with anti-
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NMDAR or anti-AMPAR encephalitis induces surface receptor loss, due to receptor 
crosslinking and internalization into recycling endosomes and lysosomes (Lai et al., 
2009; Hughes et al., 2010; Moscato et. al., 2014; Peng et al., 2015).  To determine 
whether GABAB1 autoantibodies similarly crosslinked and internalized surface GABAB 
receptors, cultured neurons were treated with patient CSF for 24 hours followed by 
immunostaining and image analysis obtained by confocal microscopy.  
As previously reported (Hughes et al., 2010; Moscato et al., 2014), a decrease in 
surface NMDA receptor clusters was observed after 24 h treatment with patient 
compared to control CSF (Fig. 3A-B, right patient CSF 9.6  1.4 clusters/20 m; control 
CSF 5.5  1.4 clusters/20 m; significantly different, p < 0.05; N = 2 patient and 2 control 
CSFs, 3 coverslips/patient, 4 neurons/coverslip).  To assess antibody bound clusters 
that were internalized, neurons were treated with patient CSF for 24 hours, fixed, 
permeabilized and incubated with a secondary antibody to human IgG conjugated to 
Alexa 594.  A concomitant increase in internalized receptor clusters was observed after 
24 h treatment with anti-NMDA receptor encephalitis patient compared to control CSF, 
as previously reported (Hughes et al., 2010; Moscato et al., 2014) (Fig. 3C, right; anti-
NMDA receptor encephalitis patient CSF 4.0  0.2 clusters/20 m; control CSF 0.1  0.2 
clusters/20 m; significantly different, p < 0.001). Surprisingly, no change in the density 
of surface GABAB receptor clusters was observed after 24 h treatment with patient 
compared to control CSF. Treatment with 5 patient and 5 control CSFs followed by 
analyses of receptor cluster density as well as area and intensity were used to confirm 
the lack of receptor internalization by patient GABAB1 antibodies (N = 3 experiments, 8-
15 coverslips/CSF, 4 neurons/coverslip).  Treatment of cultured hippocampal neurons 
for 24 h with patient or control CSF resulted in no change in cluster density (patient CSF 
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12.3  1.22 clusters/20 m; control CSF14.1 1.11 clusters/20 m; not significantly 
different, p = 0.29), area (patient CSF 0.17  0.008 m2; control CSF 0.18  0.008 m2, 
not significantly different, p = 0.50) or intensity (patient CSF 80.1  6.7; control CSF 78.1 
 5.3 arbitrary values; not significant, p = 0.81) (Fig. 3D-F).  Taken together, these data 
indicate that total surface GABAB1 receptors are unchanged by patient antibodies after 
24 h of treatment. No change in internalized receptor clusters was observed after 24 h 
treatment with patient compared to control CSF (Fig. 3C, left; patient CSF 0.1  0.1 
clusters/20 m; control CSF 0.1  0.1 clusters/20 m; not significantly different, p = 
0.20).    
To determine whether longer antibody exposure led to loss of surface GABAB1 
receptor clusters and/or other structural changes, neurons were treated for 1, 2, 3 and 7 
days with patient and control CSF followed by immunostaining with patient CSF to detect 
surface GABAB receptors, a commercial antibody to an intracellular GABAB receptor 
epitope to detect both intracellular and surface GABAB receptors, and Bassoon 
antibodies to stain presynaptic terminals.  No change in surface GABAB receptor clusters 
was observed after 1 to 7 days of treatment (Fig. 3D; 1 day patient 16.2  4.0 clusters/20 
m, control 15.6  4.0, p = 0.99; 2 days patient 13.7  4.9 clusters/20 m, control 13.9  
5.0, p = 0.99; 3 days patient 11.5  3.7 clusters/20 m, control 19.0  3.6, p = 0.17; 7 
days patient 14.7  5.8 clusters/20 m, control 11.6  6.0, p = 0.97; not significantly 
different, 2-way ANOVA, CSF treatment F(1,37) = 0.17, p = 0.67 followed by Holm-Sidak 
multiple comparisons).  In addition, no reduction was observed in GABAB1 receptor 
clusters recognized by the commercial GABAB antibody (Fig. 3E; 2-way ANOVA, CSF 
treatment F(1,37) = 1.46, p = 0.233).  Treatment with patient or control CSF for 1 to 7 
days did not result in a change in presynaptic terminal density visualized by staining for 
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Bassoon (Fig. 3F; 2-way ANOVA, CSF treatment F(1,39) = 0.02, p = 0.88).  
We used an alternate method to measure the quantity of surface GABAB receptors. 
Surface biotinylation followed by Western blot analysis of GABAB1 showed no difference 
between surface GABAB1 protein after either 24 h or 72 h treatment in patient or control 
CSF (Fig. 3G).  Similarly, no difference was observed in total GABAB receptor protein, 
surface GABAA or GluR1 receptor protein after 24 or 72 h treatment with patient or 
control CSF.  
Taken together, these data show that, contrary to autoantibodies from anti-NMDA 
receptor, anti-AMPA receptor or anti-GABAA receptor encephalitis patients, GABAB1 
autoantibodies do not change surface GABAB receptor cluster density or protein level, 
total receptor protein expression, internalized clusters, other synaptically localized 
receptors (GABAA, GluR1 receptors) or presynaptic terminals. 
Patient antibodies block GABAB receptor activation 
We next investigated whether patient GABAB receptor antibodies have functional 
effects on GABAB receptor mediated signaling.  We used the inhibition of action potential 
firing rate by a GABAB agonist as a functional readout of GABAB activation in cultured 
hippocampal neurons.  Cultured hippocampal neurons form networks in vitro 
characterized by spontaneous action potential firing ranging from 0.5 to 5 Hz.  Baclofen, 
a GABAB receptor specific agonist (Bowery, 1993) that inhibits action potential firing  
was used as a positive control.  Treatment with 1-100 M baclofen for 0.5-5 min 
eliminates action potential firing (Misgeld et al., 1995), likely due to inhibition of 
presynaptic terminals via GABAB1a-containing receptors (Howe et al., 1987; Harrison, 
1990; Scanziani et al., 1992). 
Consistent with previous work, whole cell recording in current clamp mode with no 
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current injection showed that cultured hippocampal neurons fired in the range of 1-10 Hz 
(mean 3.53 ± 0.91 Hz, N = 15 coverslips, 2 neurons/coverslip).  After treatment with 100 
M baclofen, the action potential firing rate was dramatically reduced to at most 0.05 Hz 
(Fig. 4A-B; mean 0.031 +/- 0.008 Hz, N = 20 coverslips, 1 neuron/coverslip).  However, 
cultured hippocampal neurons do not have a high baseline GABAB tone, because a high 
concentration (1 M) of a potent GABAB antagonist CGP55845 (Kd = 30 nM; Brugger et 
al., 1993) did not change the firing rate (data not shown).  Consistent with this, baseline 
firing rate is similar in neurons treated with either patient or control CSF (control CSF 
3.54 ± 0.92 Hz, N = 2 CSFs, ,  9 coverslips, 1 neuron/coverslip; patient CSF 2.85  0.41 
Hz, N = 3 CSFs, 15 coverslips, 1 neuron/coverslip (Fig. 4B; not significantly different, 
t(22) = 0.68, p = 0.45). 
We analyzed the block of GABAB activation by 100 µM baclofen mediated by CSF 
from several controls and patients. Baclofen (100 M) significantly reduced the firing rate 
of neurons pretreated for 24 hours with control CSF but was less efficacious in inhibiting 
the firing rate in neurons pretreated with anti-GABAB receptor encephalitis patient CSF 
(Fig. 4B). The efficacy of baclofen can be operationally defined as the relative reduction 
in the five minute average of firing rate during perfusion with baclofen relative to 
perfusion with artificial CSF. A 100 µM of baclofen was nearly maximally efficacious in 
inhibiting neurons treated with CSF from five different control patients similar to neurons 
that were not pretreated with CSF (efficacy ranges from 94.2% to 99.5%, p>0.99 for 
control CSF treated neurons compared to no treatment, N=5-8 coverslips, Dunn's 
multiple comparison post Kruskal-Wallis; Fig 4C). In contrast, neurons pretreated with 
CSF from patients 1, 2, and 3 were minimally silenced by 100 M baclofen: -1.8  5.4% 
(N = 16 coverslips, p<0.001), 10.3  6.9% (N = 5 coverslips, p=0.005), and 26.6  7.7% 
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(N = 10 coverslips, p = 0.001), respectively (mean percent of baseline  SEM, p-values 
from Dunn's multiple comparison post Kruskal-Wallis non-parametric two factor analysis; 
Fig. 4C).  These data indicate the patient GABABR1 autoantibodies are antagonists of 
GABAB receptors. 
Patient GABABR1 antibodies do not inactivate GABAB2 mediated signaling 
The above data show that patient CSF abrogates GABAB function in neurons in 
vitro without reducing the number of surface GABAB receptors.  We examined the 
possibility that patient antibodies disrupt GABAB activation by rendering them non-
functional or inactivated by using a GABAB2 agonist, CGP7930, which binds to the 
heptahelical domain of GABAB2, directly activating it, which in turn activates G-protein 
signaling even in the absence of any agonist binding to GABAB1 (Binet et al., 2004; Chen 
et al., 2005).  
Neurons were pretreated with the most potent patient CSF (patient 1), then treated 
with 2, 10, or 100 µM baclofen, and then with 100 µM CGP7930. Compared to control 
CSF treated neurons, 2, 10, or 100 uM baclofen was less efficacious in patient CSF 
treated neurons by 99  21% (p < 0.001, N = 3 coverslips), 69   17% (p = 0.001, N = 5 
coverslips) , and 55  17% (p = 0.006, N = 9 coverslips), respectively (1 neuron/coverslip 
in each condition; Holm-Sidak multiple comparisons post two-way ANOVA). Despite the 
antagonistic effect on baclofen efficacy by GABAB1 autoantibodies in patient CSF, the 
GABAB2 agonist CGP7930 (100 µM) was equally efficacious in both control CSF or 
patient CSF treated neurons (Fig. 5A and 5B; control CSF: 99.5  0.2%, patient CSF: 
99.1  0.3%; N = 4 coverslips, p = 0.98). These results indicate that patient GABAB 
autoantibodies prevent GABAB1 activation by agonists, but do not affect the ability of 
GABAB2 or downstream second messenger molecules to respond to GABAB receptor 
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mediated G protein activation. 
Patient antibodies are competitive antagonists of GABAB receptors 
To dissect the mechanism by which GABABR1 autoantibodies block GABAB 
receptor functions, we decreased the duration of exposure to autoantibodies before 
adding various doses of baclofen. In as little as 30 minutes of treatment with patient 
CSF, the efficacy of 3 M baclofen was reduced to 34  18% but the efficacy of 10 M 
(84  3%) or 100 M (99%) baclofen remained largely unchanged.  This represents a 
rightward  shift in logEC50 of baclofen-mediated neuron silencing from -6.4  0.6 in the 
absence of patient CSF to -5.3  0.02 after 30 minutes of treatment with patient CSF. By 
2.5 hours, the block of GABAB activation by patient CSF is nearly maximal with a further 
shift in logEC50 to -2.1  0.5 (Fig. 6A).  Statistical analysis confirms that the interaction of 
time x drug concentration has a significant effect on the baclofen block (F(8,96) = 6.2, 
p<0.0001).  These data suggest that the block of GABAB receptors by autoantibodies in 
patient CSF is rapid compared to the 24 hours it takes for the surface density of NMDA 
receptors to reach half-maximal level after cross-linking and internalization in anti-NMDA 
receptor encephalitis (Moscato et al., 2014). 
We evaluated the possibility that autoantibodies irreversibly bind to GABAB 
receptors and render them non-functional using a patient CSF of lower titer and thus 
potency (patient 4).  The GABAB autoantibodies in patient 4 CSF inhibit baclofen-
mediated silencing in a dose dependent manner (Fig. 6B; CSF concentration x baclofen 
concentration F(4,194) = 29.5, p<0.0001, N = 3 experiments 3 coverslips, 1 
neuron/coverslip for each condition).  After treatment with a 1:100 dilution of patient 4 
CSF, the efficacy of 3 M, 10 M and 100 M  of baclofen was nearly maximal (94  3%, 
92  3% and 96  2%, respectively). This corresponds to a logEC50 of approximately -6.6 
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 0.4. However, after treatment with a 1:20 or 1:5 dilution of patient 4 CSF, baclofen 
efficacy was greatly reduced in a CSF concentration dependent manner (1:20 CSF, 
logEC50 =  -4.7  0.07 and 1:5 CSF, logEC50 = -3.9  0.1).  Thus, increasing the 
baclofen concentration can overcome GABAB receptor block by patient GABAB 
autoantibodies, and an increasing titer of the patient CSF treatment result in a dextral 
shift in the dose-response curve of baclofen efficacy (Fig. 6B).  These data suggest that 
patient GABABR autoantibodies may be competitive antagonists of GABAB receptors. 
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Discussion 
Our work confirms that autoantibodies from anti-GABAB receptor encephalitis 
patients bind to GABAB1 receptors (Lancaster et al., 2010), and extends it several ways.  
We show that the Sushi domain present in the presynaptically localized GABAB1a isoform 
is necessary and sufficient to bind patient anti-GABAB receptor antibodies, suggesting 
that the effects of GABAB receptor antibodies occur presynaptically.  We demonstrate 
that GABAB receptor autoantibodies do not change surface GABAB receptor localization, 
in contrast to NMDA receptor autoantibodies from anti-NMDA receptor encephalitis 
patients.  GABAB receptor autoantibodies block GABAB receptor activation by baclofen, 
suggesting that the clinical manifestations of GABAB receptor autoantibodies result from 
diminished GABAB receptor function, a mechanism which, to our knowledge, has never 
been observed in any other autoimmune disease. Patient GABAB receptor 
autoantibodies do not inactivate GABAB receptors, however, because the patient 
antibody mediated baclofen block was circumvented by directly activating the GABAB2 
subunit with a selective partial allosteric agonist, CGP7930. We conclude that patient 
GABAB1 receptor autoantibodies are selective allosteric antagonists of presynaptic 
GABAB1a,2  receptors.  This work raises the clinically important hypothesis: GABABR2 
agonists may treat the intractable seizures that are the primary cause of morbidity and 
mortality in patients with anti-GABAB receptor encephalitis. 
The Sushi domain of GABAB1a is necessary and sufficient to bind autoantibodies 
from all anti-GABAB encephalitis patients we tested.  The immunodominant domain 
recognized by anti-GABAB receptor antibodies is distinct from what has been identified in 
anti-NMDAR or anti-AMPAR encephalitides.  In all anti-GABAB encephalitis patients 
tested here, autoantibodies bound to a 150 amino acid N-terminal portion of the receptor 
consisting of two Sushi domains, which are present in the 
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presynaptically localized GABAB1a subunit of GABAB receptors but not the GABAB1b 
subunit.  Autoantibodies from patients with anti-NMDA receptor or anti-AMPA receptor 
encephalitis bind to the auxiliary amino-terminal domain that is homologous to bacterial 
periplasmic amino acid binding proteins (PBPs, Gleichman et al., 2012, 2014; O’Hara et 
al., 1993).  
Similar to ionotropic glutamate receptors, Class III GPCRs, of which GABAB 
receptor is one, contain a domain homologous to bacterial periplasmic amino acid 
binding proteins, the Venus Flytrap domain, that binds ligand (Acher and Bertrand, 
2005).  Our results show that the VFT domain of GABAB1 does not bind patient 
autoantibodies. That the immunodominant domain in patients with anti-GABAB 
encephalitis is structurally distinct from that recognized by antibodies from patients with 
anti-NMDA or anti-AMPA receptor encephalitis may account for the strikingly different 
effects of these patients’ antibodies on surface receptor localization. 
In anti-NMDA, anti-AMPA and anti-GABAA receptor encephalitides, patient 
autoantibodies decrease cognate receptors at synapses and in cell membranes, 
whereas GABAB receptor autoantibodies did not change surface GABAB receptor 
localization. The target antigens in the encephalitides associated with NMDA, AMPA or 
GABAA receptors are generally present in two copies in an oligomeric configuration, e.g., 
two subunits of GluN1, GluA1, GluA2 or GABAAβ3 in heterooligomeric receptors. Thus 
two autoantibody binding sites are present on each ionotropic receptor, perhaps 
facilitating their clustering or aggregation by divalent autoantibodies. NMDA receptor 
internalization caused by antibodies from anti-NMDA receptor encephalitis patients is 
dependent on the divalency of patient IgGs (Hughes et al., 2010; Moscato et al., 2014).  
In contrast, GABAB receptors are most often present in neurons as heterodimers; 
autoantibodies thus bind to one epitope for every assembled receptor 
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on the cell surface.  This difference may explain why treatment with GABAB1 
autoantibodies does not result in GABAB receptor internalization. 
Identification of the immunodominant domain may also shed light on the 
pathophysiologic mechanism mediated by GABAB receptor autoantibodies. The GABAB1a 
subunit containing GABAB(1a,2) heterodimeric receptor is preferentially trafficked to 
pyramidal neuron axons (Vigot et al., 2006; Laviv et al., 2011; Degro et al., 2015). When 
activated, this receptor inhibits glutamate release from glutamatergic terminals 
(Biermann et al., 2010).  Either of the two Sushi domains present in GABAB1a is sufficient 
to traffic the subunit to the axonal domain (Vigot et al., 2006; Hannan et al., 2012).  
While patient autoantibodies are functional GABAB receptor antagonists, it is possible 
that autoantibodies also affect receptor trafficking and presynaptic localization by 
blocking the two Sushi domains. 
Taken together, autoantibody binding to Sushi domains, failure of autoantibodies to 
decrease surface GABAB receptors and autoantibody-mediated block of baclofen-
mediated inhibition of neuronal excitability is consistent with GABAB1 autoantibodies 
being allosteric antagonists of GABAB receptors. It is possible that antibody bound 
GABAB receptors are inactivated and cannot signal through G proteins. This seems 
unlikely, because even in saturating doses of baclofen, GABAB2 could be activated by a 
partial allosteric agonist in cells treated with patient autoantibodies. Our data can’t 
exclude the possibility that patient autoantibodies disrupt heterodimerization of ligand 
binding GABAB1 and the G-protein activating GABAB2 subunits.  However, this possibility 
seems unlikely because receptors remain activatable by saturating doses of baclofen, a 
GABAB1 agonist.  The regions of GABAB1and GABAB2 that are necessary for 
dimerization are the C-terminal coiled-coil domain and the upper lobe of the VFTs. 
Moreover, interaction between the VFTs of GABAB1 and GABAB2 increase 
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the affinity of GABAB1 for agonists and antagonists 10-100 fold (Pin et al., 2004). It is 
possible that the steric bulk of an IgG bound to the Sushi domains in GABAB1a subunit 
affects the interaction of the GABAB1 and GABAB2 VFTs, reducing the affinity of GABAB 
receptors to baclofen.  This is supported by our observation that the block of baclofen-
mediated inhibition of neuronal excitability by patient autoantibodies is surmountable by 
increasing the baclofen concentration. Together, our data suggest that patient GABAB 
autoantibodies are surmountable allosteric antagonists of GABAB receptors. 
In anti-GABAB receptor encephalitis patients, autoantibodies may contribute to 
seizures by interfering with GABA-mediated inhibition of neuronal firing. Development of 
CNS penetrant GABAB2 heptahelical domain agonists that rescue autoantibody 
antagonism in vitro may provide a viable therapeutic intervention to control the 
intractable seizures that are often the cause of death in anti-GABAB receptor 
encephalitis patients. 
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Figure 1. Cerebrospinal fluid (CSF) from patients contains antibodies that bind to 
GABAB1 receptors.  
(A) Immunostaining of mouse saggital brain sections with patient CSF shows binding in 
hippocampus, thalamus, striatum and cerebellum (brown); sections counterstained with 
hematoxylin (purple). Scale bar = 1mm. 
 (B) Immunostaining of unfixed and unpermeabilized 14 div hippocampal neurons with 
patient CSF (green), followed by permeabalization and staining with commercial 
antibodies to an intracellular GABAB1 epitope (red). Boxed area in neuron on left shown 
at higher magnification to right (scale bars = 5 um).  
(C) Immunostaining of fixed, permeabalized HEK293T cells expressing GABAB1a and 
GABAB2 with patient CSF (green) and commercial GABAB1 antibody (red). Scale bar = 
20 um.  
(D) Immunohistochemical staining of mid saggital brain sections from GABAB1 knockout 
mice (left) or wild type littermates (right) with patient CSF. In wildtype mice, patient CSF 
prominently stains hiccpocampus (hc), thalamus (th) and the striatum (str), while in 
knockout mice, patient CSF does not stain any brain structure above background. Scale 
bar = 500um. 
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Figure 2.  Sushi domains in GABAB1a are the dominant epitope for autoantibodies in 
patient CSF.  
(A) left: Diagram of the tertiary structure of GABAB receptor comprised of GABAB1 and 
GABAB2. right: Domain structure of GABAB1 comprised of Sushi domains (blue), ligand 
binding Venus Flytrap domain (pink) and seven transmembrane domain (black). The 
myc epitope in  the transfected construct and the epitope recognized by a commercial 
GABAB1 antibody are represented by a red and a blue asterisk, respectively.  
(B-E) HEK293T cells expressing wildtype (A) or deletion (B-D) GABAB1a and GABAB2 
immunostained with patient CSF (green, left column), N-terminal myc antibody (red, 
middle left column) or C-terminal intracellular GABAB1 antibody (blue, middle right 
column).  Cells expressing each deletion construct were immunostained for the N-
terminal myc and C-terminal GABAB1 epitope. (B)  Immunostaining is present in cells 
expressing full length GABAB1. (C)  Immunostaining is absent in cells expressing NTD 
deleted GABAB1.  C:  Immunostaining is present in cells expressing VFT deleted 
GABAB1, although staining appears qualitatively reduced compared to cells expressing 
full length receptors. (D)  Immunostaining is absent in cells expressing GABAB1 lacking 
both Sushi domains.  (E) HEK293T cells expressing fusion proteins of GABAB1a and a 
mouse CD8 receptor fragment.  
(F)  The GABAB1a N-terminal domain alone is sufficient to bind patient GABAB1 
antibodies (left). The VFT alone does not bind patient GABAB1 antibodies (middle; 
image was gamma shifted so background staining is apparent).  The Sushi domains 
(SD) alone are sufficient to bind to human autoantibodies (right). These data 
demonstrate that the Sushi domains are necessary and sufficient to bind patient 
GABAB1 antibodies.  Scale bars = 20 um.  
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Figure 3. Patient GABAB1 antibodies from patients with anti-GABAB receptor 
encephalitis do not reduce surface receptor clusters. 
(A)  Unfixed, unpermeabalized hippocampal neurons treated with patient or control CSF 
for 24 hours followed by immunostaining with patient CSF and anti-human Alexa 488 
conjugated secondary antibody (green).  Internalized patient IgG was visualized after 
fixation, permeabilization and immunostaining with anti-human Alexa 594 conjugated 
secondary antibody (red).  Left:  After 24 h treatment, the density of surface clusters is 
the same in patient and control CSF treated neurons, and no internalized clusters are 
detected (N = 3 patient CSF, 4-6 coverslips/patient, 4 cells/coverslip).  Right:  In 
contrast, after 24 h treatment with CSF from anti-NMDAR encephalitis patients, a 
significant reduction in surface clusters and a significant increase in internalized clusters 
are detected, as previously reported (Hughes et al., 2010; Moscato et al., 2014; N = 2 
patient CSF, 4-6 coverslips/patient, 4-5 cells/coverslip). Scale bar = 5 um. 
(B)  Quantification of immunostaining shows that after 24 h treatment, the density of 
surface GABAB1 clusters are not significantly different in patient or control CSF treated 
neurons (Student’s t test, p = 0.85), while 24 h treatment with CSF from anti-NMDA 
receptor encephalitis results in a significant reduction in surface clusters compared to 
control CSF treated neurons (Student’s t test p < 0.05).   
(C) Quantification of immunostaining shows that after 24 h treatment, few if any 
internalized GABAB1 clusters are detected in patient or control CSF (Student’s t test, p = 
0.21), while the density of internalized clusters is significantly higher in cells treated with 
CSF from anti-NMDA receptor encephalitis patients compared to controls (Student’s t 
test, p < 0.05).  
(D-F)  Duration of patient CSF treatment for up to 7 days does not affect surface 
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GABAB1 receptor cluster or presynaptic terminal density.  Quantification of surface 
GABAB1 (D), total GABAB1 (E) and presynaptic Bassoon (F) cluster density in neurons 
treated for 1, 2, 3 and 7 days with anti-GABAB1 patient or control CSF (N = 5 patient 
CSF and control samples, 8-15 coverslips/patient, 4 neurons/coverslip). 
(H)  Surface biotinylation and Western blot of surface and total protein fractions isolated 
from patient or control CSF treated neurons. Surface GABAB 1 receptor protein level is 
not different in patient or control treated neurons after 24 or 72 hrs (N = 1 patient 
sample, same samples used for 24 and 72 h treatment; 5 coverslips/patient). GABAA 
protein band controls for quantity of protein in surface fraction of protein lysates. No 
change in surface AMPA receptor protein (GluR1) or total GluR1 was observed.  MAP2 
protein band controls for the quantity of protein in the total lysate. (Right) There is no 
difference in total GABAB1 protein levels in patient or control treated neurons after 24 or 
72 hrs (N = 1 patient sample, same samples used for 24 and 72 h treatment; 5 
coverslips/patient). 
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Figure 4.  Patient GABAB1 antibodies block GABAB receptor activation. 
(A) Whole cell current clamp traces before, in presence of 100 um baclofen (solid bar) 
and after washout.  Top:  Cells treated with control CSF show block of action potential 
firing by baclofen.  Bottom:  Cells treated with patient CSF for 24 hours show no block of 
action potential firing by baclofen.  Scale bar = 60 s, 25 mV.  
(B) Quantification of firing rate in one minute bins, normalized to the mean firing rate 
between t=-3 min to t=0 min.  Solid bar indicates infusion of 100 uM baclofen for 10 
mins, beginning at t=0 min.  Data between t = 5-10 min was excluded to illustrate 
baclofen wash-on and off.  After the onset of baclofen infusion, neurons stop firing action 
potentials within 1-2 min in control CSF treated neurons (open circles).  Firing rate is not 
altered in patient CSF treated neurons (closed circles).  Repeated measures ANOVA; 
treatment X time F (13, 65) = 11.82 ; p < 0.05. 
(C) Efficacy of 100 uM baclofen in neurons treated for 24 hours with 1:100 of CSF from 
patients or controls. Efficacy is defined as the relative reduction in the five minute 
average of firing rate of neurons during perfusion with baclofen relative to perfusion with 
artificial CSF. Numerically, it is [1 – (average firing rate in region b/ average firing rate in 
region a)] where regions a and b are labelled in Fig 4A. In 100 uM baclofen, baclofen is 
maximally efficacious in control CSF treated neurons (gray circles, N = 6 control CSF, 5-
20 coverslips/sample, 1 neuron/coverslip).  Efficacy of 100 uM baclofen is reduced after 
treatment with patient CSF (N = 3 patient CSF, 5-15 coverslips/sample, 1 
neuron/coverslip; significantly different from control CSF, Dunn's multiple comparison 
post Kruskal-Wallis non-parametric two factor analysis of variation, p = 0.001). 
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Figure 5. Patient GABABR1 antibodies do not inactivate GABAB2 mediated signaling 
(A) Whole cell current clamp trace during perfusion with the indicated concentrations of 
either the GABAB1 binding agonist, baclofen or the GABAB2 binding agonist, CGP 7930 
from a cultured hippocampal neuron treated for 24 hours with 1:100 of CSF from patient 
1. Scale bar = 60 s, 25 mV.  
(B) Efficacy of baclofen or CGP7930 at inhibiting firing in cultured neurons treated with 
1:100 of CSF from patient 1. Despite being able to reduce the efficacy of baclofen even 
at a concentration of baclofen at 100uM, treatment with patient CSF (black circles) is 
unable to reduce the ability of CGP9730 at 100uM to silence neurons identically whether 
they are treated with patient or control CSF (p = 0.40; Holm-Sidak multiplicity correction) 
  
 
90 
 
  
 
91 
Figure 6. GABAB1 autoantibodies are allosteric antagonists of GABAB receptors. 
(A) Time course of onset of GABAB1 autoantibody mediated block of GABAB1 
activation. Neurons were recorded after indicated duration of treatment with CSF from 
case 1 in the presence of 3uM (light gray circles), 10uM (dark gray circles) or 100uM 
(black circles) of baclofen. With increasing duration of exposure to GABAB1 
autoantibodies, neurons required increasingly higher doses of baclofen to circumvent the 
block on GABAB1 activation by antibodies. By 2.5 hours or treatment, even 100 uM of 
baclofen was insufficient to overcome the antibody block of GABAB activation (ANOVA 
Treatment duration X baclofen concentration F(8, 96) = 6.271; p<0.05) . 
(B) Dose response of increasing concentration of GABAB1 autoantibodies. A lower titer 
CSF (case 4) was used, which when used for treating neurons at 1:100 does not block 
GABAB activation by baclofen. But after treatment with higher concentrations of CSF, 
neurons are inhibited by baclofen only at 100uM (ANOVA, CSF concentration X baclofen 
concentration F(4, 194) = 29.49; p<0.05) 
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CHAPTER 3. Passive transfer model of anti-NMDA receptor 
encephalitis 
Adapted from:  Jesús Planagumà et al. Brain 2015;138:94-109 
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Abstract 
Anti-N-methyl D-aspartate receptor (NMDAR) encephalitis is a severe 
neuropsychiatric disorder that associates with prominent memory and behavioral 
deficits. Patients’ antibodies react with the N-terminal domain of the GluN1 (previously 
known as NR1) subunit of NMDAR causing in cultured neurons a selective and 
reversible internalization of cell-surface receptors. These effects and the frequent 
response to immunotherapy have suggested an antibody-mediated pathogenesis, but to 
date there is no animal model showing that patients’ antibodies cause memory and 
behavioral deficits. To develop such a model, C57BL6/J mice underwent placement of 
ventricular catheters connected to osmotic pumps that delivered a continuous infusion of 
patients’ or control cerebrospinal fluid (flow rate 0.25 µl/h, 14 days). During and after the 
infusion period standardized tests were applied, including tasks to assess memory 
(novel object recognition in open field and V-maze paradigms), anhedonic behaviors 
(sucrose preference test), depressive-like behaviors (tail suspension, forced swimming 
tests), anxiety (black and white, elevated plus maze tests), aggressiveness (resident-
intruder test), and locomotor activity (horizontal and vertical). Animals sacrificed at Days 
5, 13, 18, 26 and 46 were examined for brain-bound antibodies and the antibody effects 
on total and synaptic NMDAR clusters and protein concentration using confocal 
microscopy and immunoblot analysis. These experiments showed that animals infused 
with patients’ cerebrospinal fluid, but not control cerebrospinal fluid, developed 
progressive memory deficits, and anhedonic and depressive-like behaviors, without 
affecting other behavioral or locomotor tasks. Memory deficits gradually worsened until 
Day 18 (4 days after the infusion stopped) and all symptoms resolved over the next 
week. Accompanying brain tissue studies showed progressive increase of brain-bound 
human antibodies, predominantly in the hippocampus (maximal on Days 13–18), that 
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after acid extraction and characterization with GluN1-expressing human embryonic 
kidney cells were confirmed to be against the NMDAR. Confocal microscopy and 
immunoblot analysis of the hippocampus showed progressive decrease of the density of 
total and synaptic NMDAR clusters and total NMDAR protein concentration (maximal on 
Day 18), without affecting the post-synaptic density protein 95 (PSD95) and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. These effects occurred in 
parallel with memory and other behavioral deficits and gradually improved after Day 18, 
with reversibility of symptoms accompanied by a decrease of brain-bound antibodies 
and restoration of NMDAR levels. Overall, these findings establish a link between 
memory and behavioral deficits and antibody-mediated reduction of NMDAR, provide the 
biological basis by which removal of antibodies and antibody-producing cells improve 
neurological function, and offer a model for testing experimental therapies in this and 
similar disorders. 
Introduction 
Memory, learning, and behaviour depend on the proper function of the excitatory 
glutamate N-methyl D-aspartate receptor (NMDAR) and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR) and underlying mechanisms of synaptic 
plasticity (Lau and Zukin, 2007; Shepherd and Huganir, 2007). The critical role of 
NMDAR in these functions has been shown in animal models in which the NMDAR are 
altered genetically (Mohn et al., 1999; Belforte et al., 2010) or pharmacologically 
(Jentsch and Roth, 1999; Mouri et al., 2007). In humans this evidence comes from more 
indirect observations such as studies investigating the effects of phencyclidine or 
ketamine (non-competitive antagonists of NMDAR that cause psychosis) (Weiner et al., 
2000; Gunduz-Bruce, 2009), and brain tissue studies of patients with schizophrenia or 
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Alzheimer’s disease in which several molecular pathways that modulate glutamate 
receptor trafficking or function are affected (Snyder et al., 2005; Hahn et al., 2006). In 
2007 we identified a novel disorder (anti-NMDAR encephalitis) that occurs with highly 
specific antibodies against extracellular epitopes located at the amino terminal domain of 
the GluN1 subunit of NMDAR (Dalmau et al., 2007; Gleichman et al., 2012). The 
resulting syndrome resembles the spectrum of symptoms that occurs in genetic or 
pharmacologic models of NMDAR hypofunction, including memory loss and 
neuropsychiatric alterations ranging from psychosis to coma (Dalmau et al., 2008; Irani 
et al., 2010; Viaccoz et al., 2014). Regardless of the type of presentation, most patients 
develop severe problems forming new memories and amnesia of the disease. 
Symptoms are usually accompanied by systemic and intrathecal synthesis of antibodies, 
the latter likely produced by plasma cells contained in brain inflammatory infiltrates 
(Dalmau et al., 2008; Martinez-Hernandez et al., 2011). These long-lived plasma cells 
and persistent antibody synthesis may explain the lengthy symptoms of most patients 
(average hospitalization 3 months) (Dalmau et al., 2008). Yet, despite the severity and 
duration of the disease, 80% of the patients have substantial recovery after 
immunotherapy (accompanied by removal of an underlying tumor, usually an ovarian 
teratoma, when appropriate), or sometimes spontaneously (Iizuka et al., 2008; Titulaer 
et al., 2013). 
Investigations on the potential pathogenic role of patients’ antibodies using cultured 
neurons showed that the antibodies caused crosslinking and selective internalization of 
NMDARs that correlated with the antibody titers, and these effects were reversible after 
removing the antibodies (Hughes et al., 2010; Mikasova et al., 2012). In contrast, 
patients’ antibodies did not alter the localization or expression of other synaptic proteins, 
number of synapses, dendritic spines, dendritic complexity, or cell 
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survival (Hughes et al., 2010). In parallel experiments, the density of NMDAR was also 
significantly reduced in the hippocampus of rats infused with patients’ antibodies, a 
finding comparable to that observed in the hippocampus of autopsied patients (Hughes 
et al., 2010). Overall, these studies suggested an antibody-mediated pathogenesis, but 
the demonstration that patients’ antibodies caused symptoms remained pending. 
Modelling symptoms and showing that these correlate with antibody-mediated reduction 
of NMDAR would prove the pathogenicity of patients’ antibodies, support the use of 
treatments directed toward decreasing the levels of antibodies or antibody-producing 
cells, and help to investigate experimental therapies in this and similar disorders. We 
report here such a model using continuous 14-day cerebroventricular infusion of 
patients’ CSF in mice. The aims were to determine (i) if patients’ antibodies altered 
memory and behaviour; (ii) whether mice symptoms correlated with brain antibody-
binding and reduction of NMDAR; and (iii) whether the clinical and molecular alterations 
recovered after stopping the antibody infusion. 
Materials and methods 
Animals 
Male C57BL6/J mice (Charles River), 8–10 weeks old (25–30 g) were housed in 
cages of five until 1 week before surgery when they were housed individually. The room 
was maintained at a controlled temperature (21 ± 1°C) and humidity (55 ± 10%) with 
illumination at 12-h cycles; food and water were available ad libitum. All experiments 
were performed during the light phase, and animals were habituated to the experimental 
room for 1 week before starting the tests. All procedures were conducted in accordance 
with standard ethical guidelines (European Communities Directive 86/609/EU) and 
approved by the local ethical committees: Comitè Ètic d’Experimentació Animal, Institut 
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Municipal d’Assistència Sanitària (Universitat Pompeu Fabra), and Institutional Animal 
Care and Use Committee (University of Pennsylvania). 
Patients’ CSF samples 
CSF from 25 patients with high titre NMDAR antibodies (all >1:320) were pooled 
and used for cerebroventricular infusion. CSF from 25 subjects without NMDAR 
antibodies (11 with normal pressure hydrocephalus and 14 with non-inflammatory CNS 
disorders) were similarly pooled and used as controls. Before loading the osmotic pumps 
(discussed below), the pooled CSF samples from patients and controls were dialyzed 
(Slide-A-Lyzer 7K, Thermo) against sterile phosphate-buffered saline (PBS) overnight at 
4°C, and the concentration of total IgG normalized to the CSF physiologic concentration 
of 2 mg/dl. All mice received the same pooled CSF either from patients or controls. 
Studies were approved by the institutional review board of Hospital Clínic and Institut 
d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona. 
Surgery, placement of ventricular catheters and osmotic pumps 
Cerebroventricular infusion of CSF was performed using osmotic pumps (model 
1002, Alzet) with the following characteristics: volume 100 µl, flow rate 0.25 µl/h, and 
duration 14 days. Twenty-four hours before surgery, two osmotic pumps per animal were 
each loaded with 100 µl of patient or control CSF. The pumps were then connected to a 
0.28 mm IM (internal diameter) polyethylene tube (C314CT, PlasticsOne) and left 
overnight in sterile PBS at 37°C. The next day, mice were deeply anaesthetized by 
intraperitoneal injection of a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg) 
along with subcutaneous administration of the analgesic meloxicam (1 mg/kg). Mice 
were then placed in a stereotaxic frame, and a bilateral catheter (PlasticsOne, model 
3280PD-2.0/SP) was inserted into the ventricles (0.02 mm anterior and 1.00 mm lateral 
from bregma, depth 0.22 mm) and secured with dental cement. Each arm 
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of the catheter was connected to one osmotic pump, which was subcutaneously 
implanted on the back of the mice. Appropriate ventricular placement of the catheters 
was assessed in randomly selected mice injecting methylene blue through the catheters 
(Fig. 1A–C). 
 
Cognitive tasks 
All behavioral tasks were performed by researchers blinded to experimental 
conditions using standardized tests reported by us (Maldonado et al., 1970; Filliol et al., 
2000; Berrendero et al., 2005; Bura et al., 2007, 2010, 2013; Aso et al., 2008; 
Puighermanal et al., 2009; Burokas et al., 2012; Llorente-Berzal et al., 2013) and others 
(Porsolt et al., 1977; Crawley and Goodwin, 1980; Handley and Mithani, 1984; Steru et 
al., 1985; Konig et al., 1996; Caille et al., 1999; Strekalova et al., 2006; Taglialatela et 
al., 2009; Ennaceur, 2010) and following the schedule summarized in Fig. 1D. The tasks 
were aimed to assess memory (novel object recognition in open field and V-maze), 
anhedonic behaviours (sucrose preference test), depressive-like behaviours (tail 
suspension, and forced swimming tests), anxiety (black and white and elevated plus 
maze tests), aggressiveness (resident-intruder test) and locomotor activity (horizontal 
and vertical activity assessment). A brief description of each task is provided in the 
Supplementary material. 
 
Brain tissue processing 
To determine the effects of patients’ antibodies on mouse brain, animals were 
sacrificed at the indicated time points (Fig. 1D, Days 5, 13, 18, 26 and 46) with CO2. 
Brains were harvested, sagittally split, and transferred to ice-cold PBS. Half of the brain 
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was fixed by immersion in 4% paraformaldehyde (PFA) for 1 h at 4°C, cryoprotected with 
40% sucrose for 48 h at 4°C, embedded with freezing media, and snap-frozen with 
isopentane chilled with liquid nitrogen. The other half-brain was used for dissection of 
hippocampus and cerebellum for IgG and protein extraction (see below). 
Immunohistochemistry and quantitative peroxidase staining 
For determination of antibodies bound to brain tissue using immunoperoxidase 
staining, 7-µm thick tissue sections were sequentially incubated with 0.25% H2O2 for 10 
min at 4°C, 5% goat serum for 15 min at room temperature, biotinylated goat anti-human 
IgG (1:2000, Vector labs) overnight at 4°C, and the reactivity developed using avidin-
biotin-peroxidase and diaminobenzidine. Sections were mildly counterstained with 
haematoxylin, and results photographed under a Leica DMD108 microscope. Images 
were prepared creating a mask for diaminobenzidine color, converting the mask to 
greyscale intensities, and inverting the pixels using Adobe Photoshop CS6 package. 
Hippocampal, frontal cortex, striatum and cerebellar regions were manually outlined; 
intensity and area were quantified in two serial sections using the public domain Fiji 
ImageJ software (http://fiji.sc/Fiji). Values were divided by area and normalized to the 
group with the highest mean (defined as 100%, patients’ CSF treated animals sacrificed 
at Day 18). 
Immunofluorescence and confocal microscopy with brain tissue 
For determination of antibodies bound to brain tissue using immunofluorescence, 5 
µm-thick tissue sections were blocked with 5% goat serum and 1% bovine serum 
albumin for 60 min at room temperature, and incubated overnight at 4°C with Alexa 
Fluor® 488 goat anti-human IgG (A11013, diluted 1:1000, Molecular Probes/ Life 
Technologies). Slides were then mounted with ProLong® Gold (P36930, Molecular 
Probes) and results scanned under a LSM710 Zeiss confocal microscope. 
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Sections from all animals were analyzed in parallel. Quantification of fluorescent 
intensity in areas of CA1, CA3 and dentate gyrus was done using Fiji ImageJ software. 
Background was subtracted and intensity divided by area. Mean intensity of IgG 
immunostaining in animals treated with patients’ CSF and sacrificed at Day 18 was 
defined as 100%. 
To determine the effects of patients’ antibodies on total and synaptic NMDAR 
clusters and PSD95, non-permeabilized 5-µm thick sections were blocked with 5% goat 
serum and 1% bovine serum albumin as above, incubated with human CSF antibodies 
for 2 h at room temperature, washed with PBS, permeabilized with Triton™ X-100 0.3% 
for 10 min at room temperature, and incubated with rabbit polyclonal antibody against 
PSD95 (diluted 1:250, Clone 18258 Abcam) overnight at 4°C. Next day, the slides were 
washed and incubated with the corresponding secondary antibodies, Alexa Fluor® 594 
goat anti-human IgG and Alexa Fluor® 488 goat anti-rabbit IgG (A-11014, A-11008, both 
diluted 1:1000, Molecular Probes) for 1 h at room temperature. Slides were mounted as 
above and results scanned with a confocal microscope (Zeiss LSM710) with EC-Plan 
NEOFLUAR CS ×100/1.3 NA oil objective. Standardized z-stacks including 50 optical 
images were acquired from five different, equally spaced areas of CA1, CA3 and dentate 
gyrus of hippocampus using sequential scanning, 1024 × 1024 lateral resolution, and 
Nyquist optimized z-sampling frequency. Images were deconvolved with 20 iterations 
using theoretical point spread functions and maximum likelihood estimation algorithms of 
Huygens Essential software (Scientific Volume Imaging). For cluster density analysis a 
spot detection algorithm from Imaris suite 7.6.4 (Bitplane) was used based on automatic 
segmentation of the images to spots (Banovic et al., 2010). Density of clusters was 
expressed as spots/µm3. Three-dimensional colocalization of clusters (e.g. NMDAR and 
PSD95) was done using a spot co- localization algorithm implemented in 
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Imaris suite 7.6.4. Synaptic localization was defined as co-localization of NMDAR or 
AMPAR with post-synaptic PSD95. Synaptic cluster density was expressed as 
colocalized spots/µm3. For each animal, five identical image stacks in each hippocampal 
area (CA1, CA2 and dentate gyrus) were acquired and the mean densities calculated for 
total and synaptic NMDAR and AMPAR. Densities were normalized to the mean density 
of control CSF treated animals (100%). For the AMPAR the antibody used was guinea 
pig GluA1 antibody (1:100, clone AGP-009, Alomone), and as secondary antibody Alexa 
Fluor® 594 goat anti-guinea pig IgG (A11076, 1:1000, Molecular Probes). 
The presence of apoptosis, cellular infiltrates, and complement was assessed in 
the hippocampal region (CA3) in mice sacrificed on Day 18 and corresponding controls. 
Apoptosis was determined by standard terminal deoxynucleotidyl transferase mediated 
biotinylated UTP nick end labelling (TUNEL) using the TACS 2TdT-Fluor in situ 
apoptosis detection kit (Trevigen), and immunolabelling of cleaved caspase 3 (1:200, 
#9661 Cell Signalling, Technologies) using a goat anti-rabbit Alexa Fluor® 488 as 
secondary antibody (1:1000 Molecular Probes). The presence of complement was 
assessed using rabbit anti-mouse C5b-9 (1:500, Abcam) and Alexa Fluor® 488 goat 
anti-rabbit IgG (1:500, #A11008, Molecular Probes). Immunolabelling for T and B 
lymphocytes was done using rabbit anti-mouse CD3 (1:1000, #ab16669 Abcam) 
followed by secondary antibody goat anti-rabbit Alexa Fluor® 488 (1:1000, Molecular 
Probes), and rat anti-CD45R (1/10000, #ab64100) followed by goat anti-rat Alexa Fluor® 
594 (1/1000, #A-11007 Molecular Probes). Results were scanned with a confocal 
microscope Zeiss LSM710. 
Extraction of human IgG bound to mice brain 
Under a dissection microscope (Zeiss stereomicroscope, Stemi 2000), the 
hippocampus and cerebellum were isolated, weighed, snap-frozen, and 
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stored at −80°C. Tissue (10 mg) was homogenized in 0.5 ml ice-cold PBS with protease 
inhibitors (Sigma-Aldrich) and centrifuged at 16 000g for 5 min. All steps were performed 
at 4°C. Washing was repeated four times to remove unbound IgG. The last wash was 
done in 100 µl and the supernatant saved as pre-extraction fraction. To extract the 
specifically bound antibodies, the pellet was solubilized for 5 min in acid (86 µl 0.1 M Na-
citrate buffer pH 2.7), centrifuged at 16 000g for 5 min, and the supernatant neutralized 
with 14 µl 1.5 M Tris pH 8.8, and used to determine the presence of NMDAR (GluN1) 
antibodies (see below). 
Immunofluorescence with HEK293 cells expressing GluN1 
The presence of GluN1 antibodies in IgG extracts from brain was determined using 
a HEK293 cell-based assay expressing GluN1, as reported (Dalmau et al., 2008). After 
fixation with 4% paraformaldehyde and permeabilization with 0.3% Triton™ X-100, cells 
were blocked with 1% bovine serum albumin for 90 min, and incubated with undiluted 
acid-extracted IgG or pre-extraction fraction from brain of infused mice, at 4°C overnight. 
The next day, cells were washed and incubated with a mouse monoclonal antibody 
against a non-competing GluN1 epitope located at amino acid 660-811 (1:20 000; clone 
MAB363, Millipore) for 1 h at room temperature, followed by the corresponding Alexa 
Fluor® secondary antibodies (A11013, A11032, both diluted 1:1000, Molecular Probes) 
for 1 h at room temperature. The titre of positive samples was calculated by serial 
dilutions until the reactivity was no longer visible. Results were photographed under a 
fluorescence microscope using Zeiss Axiovision software. 
Immunoblot analyses 
Total protein from hippocampus and cerebellum was obtained by dissecting these 
regions from 20-µm thick paraformaldehyde-fixed sagittal mouse brain sections on glass 
slides at 4°C under a Zeiss stereomicroscope (Stemi 2000). Two 
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consecutive sections of isolated hippocampus or cerebellum were then transferred to an 
Eppendorf tube in PBS supplemented with protease inhibitors. Loading buffer (RotiLoad) 
was added, the solubilized tissue boiled for 5 min, and the proteins separated in a 10% 
SDS gel electrophoresis with semi-dry blotting on PVDF membranes. Membranes were 
blocked in 5% non-fat skimmed milk and incubated overnight at 4°C with the following 
polyclonal rabbit antibodies: GluN1 (1:1000, Sigma-Aldrich), GluR2/3 (1:1000, Abcam), 
and PSD95 (1:1000, Synaptic Systems), or a monoclonal mouse anti-β-actin (1:20 000, 
Sigma-Aldrich). Membranes were incubated with secondary antibodies for 1 h at room 
temperature (anti-rabbit IgG HRP 1:1000, anti-mouse IgG HRP 1:10 000) and analysed 
by enhanced chemiluminescence (all Amersham GE Healthcare) on a LAS4000 (GE 
Healthcare). All studies were done in duplicate. Analysed films were in the linear range 
of exposure, digitally scanned, and signals quantified using Fiji ImageJ software. The 
signal intensity of each antigen was normalized to that of actin in the same lane. The 
mean intensity of signal in control CSF treated animals was defined as 100% and all 
other intensities expressed in per cent relative to this value. 
Statistics 
Behavioural tests were analysed using repeated measures two-way ANOVA for 
tests with multiple time points (novel object recognition, sucrose preference test, 
resident-intruder test, locomotor activity), independent sample t-tests for tests with single 
time points (forced swimming test, black and white test, elevated plus maze test) or by 
Mann Whitney-U for skewed distributions (tail suspension test). Non-normally distributed 
parameters were log-transformed (black and white test, elevated plus maze test). 
Significance of NMDAR antibody titre in acid-extracted IgG fractions was calculated 
using the Kruskal-Wallis test and Dunn’s post hoc test compared to titres at Day 46. 
Human IgG intensity, confocal cluster density and immunoblot data (GluN1, 
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PSD95) from different time points or regions were analysed using two-way ANOVA with 
Sidak-Holm post hoc testing to calculate multiplicity-adjusted P-values. Confocal cluster 
density in the different hippocampal subregions (CA1, CA3, dentate gyrus) were not 
significantly different and were analysed pooled. All experiments were assessed visually 
for outliers (e.g. one animal with very different results from the other animals at the same 
time point), but none were identified, so measurements were pooled per time point and 
treatment (patient or control CSF). For confocal AMPAR cluster density measured at 
single time points, independent sample t-tests were used. A P-value of <0.05 was 
considered significant in post hoc testing after correction for multiple testing (Sidak-
Holm). In the two-way ANOVA the cut-off for interaction between two factors was set at 
0.10; if the P-value for interaction was <0.10, the effects of treatment were considered 
for the separate time points (post hoc analysis). All tests were done using GraphPad 
Prism (Version 6). 
Results 
One-hundred and eleven mice were included in the studies, 56 for cognitive and 
behavioural tests, and 55 for assessment of antibody binding to brain and the effects on 
total and synaptic NMDAR (Fig. 1). 
Cerebroventricular infusion of patients’ CSF alters memory and behaviour in mice 
The most robust effect during the 14-day infusion of patients’ CSF was on the novel 
object recognition test in both the open field and V-maze paradigms (Fig. 2A and B). 
Compared with animals infused with control CSF, those infused with patients’ CSF 
showed a progressive decrease of the object recognition index, indicative of a memory 
deficit (Bura et al., 2007; Puighermanal et al., 2009; Taglialatela et al., 2009). The 
memory deficit became significant on Day 10 and was maximal on Day 18 (4 days after 
 
112 
the infusion of CSF had stopped). On Day 25, the object recognition index had 
normalized and was similar to that of animals treated with control CSF (Fig. 2A and B). 
For all time-points, the total time spent exploring both objects (internal control) was 
similar in animals infused with control or patients’ CSF (Supplementary Table 1). 
The preference to drink sweetened water (sucrose preference test) was used as a 
measure of anhedonic behaviour. Mice infused with patients’ CSF and tested during the 
infusion period (Day 10) had less preference for sucrose compared with mice infused 
with control CSF (Fig. 2C). In contrast, the same mice tested 10 days after the infusion 
of CSF had stopped (Day 24) showed a preference for sucrose similar to that of the 
control mice. The total consumption of water with and without sucrose was similar in 
both groups (internal control, Supplementary Table 1). In addition, two tests of 
depressive-like behaviour were performed. The tail suspension test, performed on Day 
12, showed that animals infused with patients’ CSF had longer periods of immobility 
compared with those infused with control CSF (Fig. 2D). In contrast, 6 days after the 
infusion of CSF had stopped (Day 20), no differences were noted with the forced 
swimming test (examining immobility in inescapable situations; Fig. 2E and 
Supplementary Table 1). Overall, these findings suggest that the infusion of NMDAR 
antibodies was associated with anhedonic and depressive-like behaviours. 
In contrast to the prominent memory deficit, along with anhedonia and depressive 
behaviour, no significant differences were noted in tests of anxiety (black and white test, 
elevated plus maze test), aggression (resident-intruder test) and locomotor activity (Fig. 
3A–D). 
Patients’ antibodies bind to NMDAR in mouse brain 
Animals infused with patients’ CSF, but not control CSF, had progressively 
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increasing human IgG immunostaining (representing IgG bound to brain) that correlated 
with the duration of the infusion. The distribution of IgG immunostaining predominated in 
regions with high density of NMDAR, mainly the hippocampus (Fig. 4A), resembling that 
obtained with brain sections directly incubated with patients’ CSF or a monoclonal 
antibody against GluN1 (Dalmau et al., 2008). Upon quantification of immunostaining, 
the maximal antibody binding was identified in mice sacrificed on Day 18, which had 
received 14 days of CSF infusion, compared with mice sacrificed on Days 5 or 13 (Fig. 
4B and C). In animals sacrificed on Days 26 and 46 the presence of IgG immunostaining 
progressively decreased. In frontal cortex the dynamics of IgG binding were similar to 
those of the hippocampus (Supplementary Fig. 1), but the amount of IgG was 
substantially less; in other brain regions such as the cerebellum and striatum, the IgG 
immunostaining was sparse and not significantly different between animals infused with 
patients’ CSF or control CSF (data not shown). 
Studies with immunofluorescence and confocal microscopy showed that in animals 
infused with patients’ CSF the presence of hippocampal IgG was visible as a punctate 
immunolabelling on the surface of neurons and neuronal processes in contrast to mice 
infused with control CSF where minor amounts of IgG reactivity without preference for 
neuronal structures were noted (Fig. 4D–G). In addition, the amount of human IgG 
bound to all selected regions of hippocampus was significantly higher than in the control 
group (Fig. 4H). 
 
To determine if the IgG immunostaining represented brain-bound NMDAR 
antibodies, IgG was extracted from several brain regions and examined for reactivity 
with HEK cells expressing GluN1. These studies showed that the IgG extracted from 
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hippocampus of mice infused with patients’ CSF reacted specifically with GluN1 (Fig. 
5A). The NMDAR antibody concentration in the extracts correlated with the duration of 
infusion of CSF; it increased until Day 13, reached the maximal concentration on Days 
13–18, and decreased afterwards (Fig. 5A and C). NMDAR antibodies were also 
detected in IgG extracts from other brain regions (frontal cortex, cerebellum) but at lower 
concentration to that obtained from hippocampus (Fig. 5D). Demonstration that the 
extracted antibodies were specifically bound to the NMDAR was provided by the lack of 
GluN1 reactivity in the pre-extraction fractions (Fig. 5B and E). Parallel studies with 
tissue from animals infused with control CSF did not show NMDAR antibodies 
(Supplementary Fig. 2). 
Effects of patients’ antibodies on NMDAR 
To determine the effects of patients’ antibodies on NMDAR, we focused on the 
hippocampus, which was the region with maximal concentration of NMDAR-bound 
antibodies. Compared with animals infused with control CSF, those infused with patients' 
CSF had on Days 13 and 18 a significant decrease of the density of total and synaptic 
hippocampal NMDAR clusters followed by a gradual recovery after Day 18 (pooled 
analysis of CA1, CA3 and dentate gyrus; Fig. 6A–D). No significant differences in 
between hippocampal subregions (CA1, CA3, dentate gyrus) were observed (not 
shown). In contrast, patients’ antibodies did not alter the density of PSD95 or AMPAR 
clusters (Fig. 6E and F). 
Immunoblot analysis of total protein extracted from hippocampus showed that on 
Days 13 and 18, mice infused with patients’ CSF had a significant decrease of total 
NMDAR protein concentration compared with mice infused with control CSF (Fig. 7A 
and B). The magnitude of this effect was greater in animals with higher concentration of 
IgG bound to hippocampus (Fig. 7C). Parallel studies examining the effect 
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on the protein concentrations of PSD95 (Fig. 7A and E) and AMPAR (Fig. 7D) 
demonstrated no significant differences between mice infused with patients’ CSF or 
control CSF. 
In cerebellum, no significant effects on the cluster density or total protein 
concentration of NMDAR, PSD95 and AMPAR were noted in animals infused with 
patients’ CSF compared to those infused with control CSF (data not shown). 
Immunohistochemical studies for neuronal apoptosis, infiltrates of T or B cells, and 
deposits of complement in hippocampus of animals infused with patients’ or control CSF, 
examined on Day 18, showed no abnormalities (Fig. 8). 
Discussion 
We report that passive transfer of NMDAR antibodies by continuous ventricular 
infusion of CSF from patients with anti-NMDAR encephalitis causes memory and 
behavioural deficits in mice, and that the effects are likely mediated by the binding of 
antibodies to NMDAR resulting in a specific decrease of the density of these receptors. 
Data from earlier reports showing that despite the severity and duration of symptoms, 
most patients with anti-NMDAR encephalitis respond to immunotherapy (Gresa-Arribas 
et al., 2014), and findings at the cellular level demonstrating that patients’ antibodies 
cause a titre-dependent decrease of synaptic NMDAR receptors fulfilled most of the 
Witebsky’s criteria for an antibody-mediated disease (Rose and Bona, 1993), but the 
transfer of symptoms to animals was pending. In the current study, four sets of 
experiments satisfy this postulate: (i) the development of symptoms in animals infused 
with patients’ CSF, but not control CSF; (ii) the demonstration that the infused antibodies 
reacted predominantly with brain regions with high density of NMDAR (e.g. 
hippocampus) and specifically recognized these receptors; (iii) the 
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identification of a selective decrease of the density of total and synaptic NMDAR clusters 
and total NMDAR protein concentration without affecting PSD95, and that these effects 
correlated with the concentration of brain-bound antibodies; and (iv) the correlation 
noted between the intensity of the abovementioned findings and time-course of patients’ 
antibody infusion, as well as between the reversibility of symptoms and restoration of 
NMDAR levels after stopping the infusion of CSF antibodies. 
Approximately 75% of patients with anti-NMDAR encephalitis present with mood 
and psychiatric alterations ranging from manic or depressive behaviour to psychosis, 
often followed by stereotyped movements, seizures, or decreased level of 
consciousness (Kayser et al., 2013; Titulaer et al., 2013). Regardless of the 
presentation, most patients develop severe problems forming new memories and have 
amnesia of the disease. Close examination during the phase of recovery shows, in some 
patients, impairment in the visual recognition of objects or faces (e.g. physicians, nurses) 
(Frechette et al., 2011). Owing to the wide range of symptoms of the disease and lack of 
previous studies examining the distribution of brain tissue NMDAR-antibody binding 
when these antibodies are infused intraventricularly, we used standardized memory and 
behavioural tests. The most notable effects were observed in the tests of memory (novel 
object recognition) using different groups of animals in two different paradigms (open 
field and V-maze). While the first depends predominantly on normal hippocampal 
function, the second is dependent of perirhinal-hippocampal structures (Winters et al., 
2004). Compared with animals infused with control CSF, those infused with patients’ 
CSF developed progressive memory deficits, which were maximal on Days 13–18 when 
the highest concentration of brain-bound NMDAR antibodies and lowest density of 
NMDAR occurred. Other paradigms affected were related to depressive-like behaviours 
(tail suspension test) and anhedonic behaviours (sucrose preference test). 
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We did not find significant abnormalities in the tests of aggression and anxiety, which are 
often present in the human disease, or in locomotor activity (an expected finding given 
that paralysis rarely occurs in patients). 
The high levels of brain-bound NMDAR antibodies between Days 13–18 suggests 
that after stopping the infusion of patients’ CSF on Day 14, the NMDAR antibodies 
continued being distributed from mice cerebroventricular system to parenchyma. This 
distribution occurred slowly; for example, 5 days after starting the infusion of patients’ 
CSF the amount of NMDAR antibodies that had reached the hippocampus was very 
limited compared to that seen on Days 13–18 (shown in Fig. 4B). Moreover, previous 
studies using cultured neurons treated with patients’ CSF showed that once the 
antibodies bound to the NMDARs, the reduction of receptors was microscopically visible 
in 2 h but it took 12 h to result in the lowest receptor density. Subsequently, there was a 
steady state of low NMDAR density for as long as the neurons were exposed to patients’ 
antibodies (Moscato et al., 2014). Together, these findings explain the progressive 
worsening of symptoms along with continued antibody binding and decrease of NMDAR 
for at least 4 days after the ventricular infusion stops and the subsequent recovery 
starts. 
Although the hippocampus was the region with the highest concentration of brain-
bound NMDAR antibodies, these antibodies were also extracted from cerebral cortex or 
cerebellum though at much lower levels. The higher concentration of antibodies and 
predominant decrease of NMDAR in the hippocampus are consistent with the 
predominant binding of human antibodies to this brain region when sections of rodent 
brain are directly incubated with patients’ antibodies (Dalmau et al., 2007; Moscato et al., 
2014). Additionally, because of the close spatial relationship to the ventricles, the 
intraventricular infusion of human CSF antibodies might have contributed 
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to the preferential binding to the hippocampus. 
The correlation between the concentration of brain-bound antibodies and selective 
reduction of NMDAR cluster density and protein concentration was similar to that 
reported using in vitro studies with cultured rat hippocampal neurons (Hughes et al., 
2010; Moscato et al., 2014). Moreover, autopsies of patients with anti-NMDAR 
encephalitis showed that the hippocampal regions with highest concentration of brain-
bound antibodies were also the areas with lower expression of NMDAR (Dalmau et al., 
2007). In the current model, patients’ antibodies did not alter AMPAR cluster density or 
protein concentration; these findings are in line with those reported with cultured neurons 
where the clusters of AMPAR and AMPAR-mediated currents were not directly affected 
(Hughes et al., 2010). These experiments, however, did not explore whether paradigms 
that normally induce long-term potentiation, and therefore increase the number of 
synaptic AMPAR, were altered by patients’ antibodies. Mikasova et al. (2012) showed 
that neurons exposed to patients’ NMDAR antibodies failed to show an increase in cell 
surface AMPAR after induction of chemical long-term potentiation. Another study 
examining the acute metabolic effects of patients’ antibodies after injection into rat brain 
showed impairment of NMDA and AMPA-mediated synaptic function (Manto et al., 
2010). In the present model, we did not perform electrophysiological studies on acute 
slices of brain (a goal of future studies); however, there is reported evidence that 
patients’ NMDAR antibodies suppress induction of long-term potentiation when directly 
applied to mouse hippocampal slices (Zhang et al., 2012). Work with cultured neurons 
indicates that the decrease of synaptic NMDAR currents is likely a result of the antibody-
mediated low receptor levels, as no direct antibody blockade was detected (Moscato et 
al., 2014). 
Our study has limitations related to the type of disease and symptoms 
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to model. For example, different from other models of antibody-mediated CNS disorders 
where the antibodies result in characteristic symptoms (e.g. amphiphysin antibodies and 
visible muscle spasms) (Sommer et al., 2005) or focal deficits with visible tissue changes 
(e.g. AQP4 antibodies and neuromyelitis optica) (Hinson et al., 2012; Bradl and 
Lassmann, 2014), anti-NMDAR encephalitis results in a broader spectrum of symptoms 
where memory and behavioural deficits occur early, and the structural alterations are not 
visible unless the NMDAR clusters or protein concentration are measured. It is not 
surprising that in the current model the full spectrum of symptoms, such as seizures, 
dyskinesias or coma, did not occur. Studies with NMDAR antagonists have shown that 
the progression of symptoms (from behavioural and memory deficits to 
unresponsiveness with catatonic features and coma) correlated with the intensity of the 
decrease of receptor function (Javitt and Zukin, 1991). Therefore, it is likely that 
prolonged infusion or higher concentration of patients’ antibodies would cause additional 
symptoms. This is supported by the current model, in which the time course of symptom 
development, brain-bound antibody concentration, and decrease of synaptic NMDAR 
correlated well with each other. Future experiments using prolonged infusion or higher 
concentration of patients’ antibodies may also result in symptoms beyond hippocampal-
parahippocampal regions. Compared with the hippocampus, other brain regions 
normally have lower density of NMDAR, and appeared to be less accessible to the 
ventricularly infused antibodies. Direct injection of antibodies into those brain regions 
can be considered, but we previously tried bilateral hippocampal infusion using the same 
osmotic pump approach, resulting in more limited antibody diffusion and no symptoms 
(data not published). Moreover, the phenotype of the current model is likely influenced 
by the strain of mice. In this study we used C57BL6/J mice because we were interested 
in the effects on memory and behaviour, but this strain is one of the 
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most resistant to develop seizures (Ferraro et al., 2002). 
The antibody-induced depletion of synaptic NMDAR along with the similarities 
between the human disease and the phenotypes induced by NMDAR antagonists 
(phencyclidine, ketamine or MK801) have suggested points of convergence with one of 
the most influential theories of schizophrenia, the NMDA-hypofunction model (Olney and 
Farber, 1995; Kehrer et al., 2008). The presence of positive (hallucinations, delusions, 
hyperactivity) and negative (decreased motivation, flat affect, deficit of memory and 
learning) symptoms is, however, not identical among the drug-induced phenotypes and 
also varies among animal species (Javitt and Zukin, 1991). It has been suggested that 
NMDAR-bearing parvalbumin-positive GABAergic interneurons are disproportionally 
more sensitive to NMDAR antagonists than other neurons (Li et al., 2002). Interestingly, 
a genetic model of partial ablation of the GluN1 subunit of NMDAR in corticolimbic 
GABAergic interneurons resulted in symptoms partially resembling our GluN1 
immunological model of receptor depletion, including memory deficits and anhedonic 
behaviours (Belforte et al., 2010). Differences related to the underlying mechanisms 
(pharmacologic blockade, genetic or immunologic NMDAR depletion) and regions where 
the NMDAR function is depleted (general, corticolimbic, or hippocampal-
parahippocampal) likely influence the clinical phenotypes. 
Overall, the current findings provide robust evidence that antibodies from patients 
with anti-NMDAR encephalitis alter memory and behaviour through reduction of cell-
surface and synaptic NMDAR, and therefore support the use of treatments directed at 
decreasing the levels of antibodies or antibody-producing cells. This approach can now 
be adapted to (i) model other aspects of the disease by changing the duration and 
dosing of antibody infusion, or strain of mice; (ii) investigate other disorders of memory 
and behaviour that occur in association with antibodies against 
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other cell surface or synaptic proteins, such as AMPAR or GABA(B)R (Lai et al., 2009; 
Lancaster et al., 2010); and (iii) determine whether compounds such as Ephrin-B2 ligand 
that has been shown to prevent the destabilizing NMDAR crosslinking effects of patients’ 
antibodies improve or alter the course of the disease (Mikasova et al., 2012). 
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Figure 1. Experimental design and placement of ventricular catheters.  
(A) Representative coronal mouse brain section with catheter placement. Scale bar 
= 2 mm. (B and C) Coronal and sagittal mouse brain sections demonstrating 
cerebroventricular diffusion of methylene blue after ventricular infusion. Scale bars = 2 
mm. (D) Schedule of cognitive testing and animal sacrifice. At Day 0, catheters and 
osmotic pumps were placed and bilateral ventricular infusion of patients’ or control CSF 
started. Infusion lasted for 14 days. Memory [novel object recognition (NOR)], anhedonia 
[sucrose preference test (ANH)], depressive-like behaviour [tail suspension test (TST) 
and forced swimming test (FST)], anxiety [black and white test (BW) and elevated plus 
maze test (EPM)], aggressiveness [resident intruder test (RI)] and locomotor activity 
(LOC) were assessed blinded to treatment at the indicated days. The novel object 
recognition was assessed in open field and V-maze paradigms in two different cohorts of 
mice. Animals were habituated for 1 to 4 days before surgery (baseline) to novel object 
recognition, anhedonia, and locomotor activity. Red arrowheads indicate the days of 
sacrifice for studies of effects of antibodies in brain. 
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Figure 2. Infusion of CSF from patients with NMDAR antibodies causes deficits in 
memory, anhedonia and depressive-like behaviour.  
(A and B) Novel object recognition index in open field (A) or V-maze paradigms (B) in 
animals treated with patients’ CSF (grey circles) or control CSF (white circles). A high 
index indicates better object recognition memory. (C) Preference for sucrose-containing 
water in animals infused with patients' CSF (grey) or control CSF (white). Lower 
percentages indicate anhedonia. (D and E) Total time of immobility in tail-suspension 
test during the infusion period (D, Day 12) and in forced swimming test after the infusion 
period (E, Day 20). Data are presented as mean ± SEM (median ± IQR in D). Number of 
animals: patients’ CSF n = 18 (open field novel object recognition n = 8), control CSF n = 
20 (open field novel object recognition n = 10). Significance of treatment effect was 
assessed by two-way ANOVA (A–C) with an α-error of 0.05 and post hoc testing with 
Sidak-Holm adjustment (asterisks), unpaired t-test (E) or Mann-Whitney U test (D). *P < 
0.05, ***P < 0.001. See Supplementary Table 1 for detailed statistics. 
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Figure 3. Infusion of CSF from patients with NMDAR antibodies does not alter the tests 
of anxiety, aggression and locomotor activity.  
(A and B) Number of entries into bright/open compartments during a 5 min period in a 
standard black and white (A, Day 6) or elevated plus maze test (B, Day 14) in animals 
treated with patients’ CSF (filled circles) or control CSF (open circles). (C) Number of 
aggressive events over a 4-min period in a resident intruder paradigm in both treatment 
groups. (D) Horizontal (solid lines) and vertical (dashed lines) movement count over a 10 
min period in both treatment groups. Data are presented as mean ± SEM. Number of 
animals: patients’ CSF n = 18, control CSF n = 20. Statistical assessment as indicated in 
Fig. 2 and Supplementary Table 1. 
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Figure 4. Animals infused with patient’s CSF have a progressive increase of human IgG 
bound to hippocampus.  
(A and B) Immunostaining of human IgG in sagittal brain sections (A) and 
hippocampus (B) of representative animals infused with patients’ CSF (left) and control 
CSF (right), sacrificed at the indicated experimental days. In animals infused with 
patients’ CSF there is a gradual increase of IgG immunostaining until Day 18, followed 
by decrease of immunostaining. Scale bars: A = 2 mm; B = 200 µm. (C) Quantification of 
intensity of human IgG immunolabelling in hippocampus of mice infused with patients’ 
CSF (dark grey columns) and control CSF (light grey columns) sacrificed at the indicated 
time points. (D–H) Confocal microscopy analysis of IgG bound to the hippocampus on 
Day 18. (D) Sagittal section of the hippocampus with areas examined at higher 
magnification in E (arrow in CA1), F (arrow heads in CA3) and G (asterisks in dentate 
gyrus). Note the fine punctate IgG immunolabelling surrounding neuronal bodies in mice 
infused with patients’ CSF; this immunolabelling is similar to that reported in brain 
sections directly incubated with patients’ antibodies, as in Dalmau et al. (2008). Scale 
bars: D = 200 µm; E–G = 10 µm. (H) Quantification of the intensity of human IgG 
immunofluorescence in the indicated areas in animals infused with patients’ CSF (dark 
grey columns) or control CSF (light grey columns). For all quantifications, mean intensity 
of IgG immunostaining in the group with the highest value (animals treated with patients’ 
CSF and sacrificed at Day 18) was defined as 100%. All data are presented as mean ± 
SEM. For each time point five animals infused with patients’ CSF and five with control 
CSF were examined. Significance of treatment effect was assessed by two-way ANOVA 
with an α-error of 0.05 (*) and post hoc testing with Sidak-Holm adjustment ($). ***, $$$P 
< 0.001; $P < 0.05. See Supplementary Table 2 for detailed statistics. 
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Figure 5. The human IgG extracted from brain of mice infused with patients’ CSF is 
specific for NMDARs.  
(A and B) HEK293 cells expressing the GluN1 subunit of the NMDAR 
immunolabelled with acid-extracted IgG fractions (top row in A) or pre-extraction 
fractions (top row in B) from hippocampus of mice infused with patients’ CSF and 
sacrificed on the indicated days. The maximal reactivity with GluN1-expressing cells was 
noted in acid-extracted IgG fractions from Days 13 and 18 (A); none of the pre-extraction 
fractions showed GluN1 reactivity (B) indicating that the reactivity of acid-extracted 
fractions corresponds to IgG antibodies that were bound to brain NMDAR receptors. The 
second row in A and B shows the reactivity with a monoclonal GluN1 antibody, and the 
third row the colocalization of immunolabelling. Scale bars = 10 µm. (C) Quantification of 
NMDAR antibody titre in IgG-extracted fractions from hippocampus of animals treated 
with patients’ CSF (n = 5 mice per each time point, except four mice for Day 5). Solid line 
= median. Significance was tested by Kruskal-Wallis with an α-error of 0.05 (asterisks) 
and post hoc testing with Dunn’s test ($). **, $$P < 0.01, ***, $$$P < 0.001. See 
Supplementary Table 2 for detailed statistics. (D and E) HEK293 cells expressing the 
GluN1 subunit of the NMDAR immunolabelled with acid-extracted IgG fractions (D) and 
pre-extraction fractions (E) from hippocampus (Hippo), cerebral cortex (Ctx) and 
cerebellum (Cb) of mice infused with patients’ CSF (Day 18). The acid-extracted IgG 
fraction from hippocampus showed higher level of NMDAR antibodies than those 
extracted from cerebral cortex (Ctx) and cerebellum (Cb). Scale bars = 10 µm. n.s = not 
significant. 
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Figure 6. Patients’ NMDAR antibodies selectively reduce the density of total and 
synaptic NMDAR clusters in hippocampus of mice.  
(A) Hippocampus of mice infused for 14 days (Day 18) with patients’ CSF (upper 
row) or control CSF (lower row) immunolabelled for PSD95 and NMDAR. Images were 
merged (merge) and post-processed to demonstrate co-localizing clusters (co-
localization). Squares in ‘co-localization’ indicate the analysed areas in CA1, CA3 and 
dentate gyrus. Scale bar = 200 µm. (B) Three-dimensional projection and analysis of the 
density of total clusters of PSD95 and NMDAR, and synaptic clusters of NMDAR 
(defined as NMDAR clusters colocalizing with PSD95) in a representative CA3 region 
(square in A ‘co-localization’). Merged images (merge, PSD95 green, NMDAR red) were 
post-processed and used to calculate the density of clusters (density = spots/µm3). 
Scale bar = 2 µm. (C–F) Quantification of the density of total (C) and synaptic (D) 
NMDAR clusters, PSD95 clusters (E), and total/synaptic AMPAR and PSD95 clusters 
(Day 18 only, F) in a pooled analysis of hippocampal subregions (CA1, CA3, dentate 
gyrus) in animals treated with patients’ CSF (dark grey) or control CSF (light grey) on the 
indicated days. Mean density of clusters in control CSF treated animals was defined as 
100%. Data are presented as mean ± SEM. For each time point five animals infused 
with patients’ CSF and five with control CSF were examined. Significance of treatment 
effect was assessed by two-way ANOVA with an α-error of 0.05 (asterisks) and post hoc 
testing with Sidak-Holm adjustment ($) (C–E) or unpaired t-test (F). *, $P < 0.05; **, $$P 
< 0.01; ***, $$$P < 0.001. See Supplementary Table 2 for detailed statistics. 
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Figure 7. Patients’ NMDAR antibodies selectively reduce the protein concentration of 
NMDAR in hippocampus of mice.  
(A) Representative immunoblots of proteins extracted from hippocampus of animals 
infused with patients’ CSF (P) or control CSF (C) sacrificed at the indicated time points 
and probed for expression of GluN1 (NMDAR), PSD95 and β-actin (loading control). 
Note that there is less visible GluN1 expression on Days 13 and 18. (B, D and E) 
Quantification of total NMDAR (B), AMPAR (D) or PSD95 (E) protein in animals treated 
with patients’ CSF (filled columns) or control CSF (open columns) sacrificed at the 
indicated time points (AMPAR Day 18 only, D). Results were normalized to β-actin 
(loading control). Mean band density of animals treated with control CSF was defined as 
100%. Data are presented as mean ± SEM. For each time point six animals infused with 
patients’ CSF and six with control CSF were examined (for Days 26 and 46, only five 
animals treated with patient’s CSF were available). Significance of treatment effect was 
assessed by two-way ANOVA with an α-error of 0.05 (asterisks) and post hoc testing 
with Sidak-Holm adjustment ($). $$P < 0.01; ***P < 0.001. See Supplementary Table 2 
for detailed statistics. (C) Correlation between concentration of human IgG bound to 
hippocampus (x-axis, highest hippocampal IgG intensity was defined as 100%) and 
hippocampal NMDAR protein concentration in mice sacrificed on Day 18 (R2 = 0.69, P = 
0.003). Filled circles: mice infused with patients’ CSF (n = 5), open circles: mice infused 
with control CSF (n = 5). 
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Figure 8. Absence of neuronal apoptosis, deposits of complement, and lymphocytic 
infiltrates in the hippocampus of mice infused with patients’ CSF.  
(A and B) TUNEL and cleaved caspase 3 immunolabelling of a representative area 
of CA3 (area with maximal IgG binding and lower NMDAR concentration) of an animal 
infused with patients’ CSF, showing lack of apoptotic cells. A section of the same region 
in an animal with transient middle cerebral artery occlusion (stroke model) shows 
apoptotic cells in the penumbra (left). (C) Same CA3 region as in (A) 
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immunostained for C5b-9 showing lack of deposit of complement. A section of the same 
region in the indicated stroke model shows presence of complement in the penumbra 
(left). (D and E) Same CA3 region as in (A) immunostained for T (CD3) and B (CD45R) 
lymphocytes showing absence of inflammatory infiltrates. A section of spleen was used 
as control tissue showing the presence of CD3 (green) and CD45R (red) cells. Scale bar 
= 10 µm. Total number of animals examined: patients’ CSF n = 5; control CSF n = 5. 
Scale bars = 20 µm. 
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Abstract 
Objective:  To report 3 patients who developed anti–N-methyl-D-aspartate receptor 
encephalitis during pregnancy. 
Design:  Case reports. 
Setting: University hospitals. 
Patients:  Three young women developed at 14, 8, and 17 weeks of gestation acute 
change of behavior, prominent psychiatric symptoms, progressive decrease of 
consciousness, seizures, dyskinesias, and autonomic dysfunction. 
Main Outcome Measures: Clinical, radiological, and immunological findings. 
Results: The 3 patients had cerebrospinal fluid pleocytosis, normal magnetic 
resonance imaging, and electroencephalogram showing slow activity. All had higher 
antibody titers in cerebrospinal fluid than in serum and 2 had ovarian teratomas that 
were removed. The pregnancy was terminated in 1 patient with recurrent bilateral 
teratomas. All patients had substantial neurological recoveries, and the 2 newborns were 
normal. Results of extensive antibody testing in 1 of the babies were negative. 
Conclusion:  The current study shows that anti-NMDAR encephalitis during 
pregnancy can have a good outcome for the mother and newborn. 
Introduction 
Anti–N-methyl-D-aspartate receptor (NMDAR) encephalitis is a synaptic 
autoimmune disorder that is likely mediated by antibodies against the NR1 subunit of the 
receptor (Dalmau et al., 2008). Despite the severity of the disorder, most patients have 
substantial recoveries. Because the disease frequently affects women of childbearing 
age and the antibody subtypes (IgG1, IgG3) can cross the placenta, there is 
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concern about the effects of the disorder during pregnancy (Tüzün et al., 2009). We 
report 3 patients who developed the disorder during pregnancy. 
Report of cases 
Clinical features from the patients are described in this section and summarized in 
the Table. Antibodies to NMDAR were detected as reported elsewhere (Dalmau et al., 
2008) and the titers were determined by serial dilution (starting at 1:10). The baby of 
patient 1 had antibody studies in the umbilical cord, serum, cerebrospinal fluid (CSF), 
and amniotic fluid. 
Case 1 
A 19-year-old woman presented at 14 weeks of gestation with 2 weeks of 
headache and malaise followed by bizarre behavior and paranoid delusions resulting in 
hospitalization. Over the course of a week, her mental status worsened until she was 
minimally responsive. She had a generalized seizure that was treated with fosphenytoin 
and lorazepam, and she was intubated for airway protection. A bedside 
electroencephalogram (EEG) revealed generalized slowing but no epileptic activity. On 
examination, she was minimally responsive to noxious stimuli, had generalized 
hyperreflexia, and moved all limbs spontaneously. Results of magnetic resonance 
imaging (MRI) and CSF studies are described in the Table. Treatment with acyclovir was 
started for presumptive viral encephalitis. 
On the third day in the intensive care unit, she developed repetitive pursing of the 
lips and furrowing of her brow without EEG correlates. These movements became more 
frequent and the dyskinesias spread to her limbs. By day 8, she developed diaphoresis, 
tachycardia, mydriasis, and hypertension. These symptoms were difficult to control 
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despite treatment with fentanyl, lorazepam, propofol, bromocriptine, and β-blockers. 
On day 5, a tracheostomy was performed. Treatment with intravenous 
immunoglobulin did not result in improvement. On day 23, an MRI of the abdomen and 
pelvis revealed a 2.5 × 3-cm left ovarian simple cyst. On day 43, NMDAR antibodies 
were identified in CSF. A second course of intravenous immunoglobulin treatment along 
with 1 g of methylprednisolone was given daily for 5 days. On day 50, a left 
oophorectomy was performed, revealing an immature teratoma. On day 52, 
plasmapheresis was initiated, with a total of 7 treatments over 2 weeks. On day 72, she 
became more alert, responded to voice, and tracked objects. Throughout the 
hospitalization, the fetus was monitored weekly by Doppler ultrasonography, showing 
normal heart tones. Obstetric ultrasonography performed at weeks 20 and 26 revealed 
normal fetal anatomy and appropriate growth for gestational age. 
The patient remained in the intensive care unit because of persistence of 
sympathetic storms. By day 107, she was following simple commands and the sedation 
was slowly weaned. On day 127, she began mouthing words. A cesarean section and 
concomitant surgical staging was performed on day 166 (at 37 weeks of gestation, 
following amniocentesis confirming fetal lung maturity). The infant weighted 6 lb 3 oz and 
Apgar scores were 3 at 1 minute and 6 at 5 minutes. All pathological specimens (left 
adnexa, pelvic lymph nodes, and peritoneal samples) were negative for tumor. Over the 
next 3 days, the patient was weaned from the ventilator and she made steady gains in 
physical therapy. By day 184, she was able to ambulate with a walker and her speech 
was fluent, but she was only oriented to self. Her progress was hampered by impulsivity, 
short-term memory loss, and physical deconditioning. Two months after discharge, she 
was functioning independently at home, although she was persistently impulsive and 
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complained of somnolence. The infant has met all developmental milestones to date. 
Case 2 
A 20-year-old woman developed change of behavior during the eighth week of 
pregnancy. She became argumentative, refused to talk and eat, and developed 
stereotyped behaviors, such as walking endlessly around a room or filling and emptying 
a glass with water. Two days before hospital admission, semirhythmic movements 
including blinking, licking, and tongue protrusion were noted. One day before admission, 
she developed hyperthermia, decreased level of consciousness, and a seizure. She had 
a history of bilateral ovarian teratomas that were removed when she was 16 years of 
age. 
At admission, she had neck stiffness, without fever, and showed repetitive orofacial 
movements. She was poorly responsive to verbal and painful stimuli and had 
generalized hyperreflexia. Ancillary test results are described in the Table. Intravenous 
acyclovir and methylprednisolone administration were started. On day 3, cardiac pauses 
up to 5 seconds were noted (Figure, A). Over the next few days, she developed 
hypersalivation and generalized tonic convulsions. On day 13, status epilepticus and 
respiratory depression led to intubation and mechanical ventilation. On day 15, a pelvic 
computed tomographic scan revealed bilateral ovarian tumors (Figure, B, arrows); 2 
days later, a left salpingo-oophorectomy and removal of both tumors was performed, 
and the pregnancy was terminated. Pathological studies confirmed bilateral mature 
teratomas. 
From days 23 to 27, she received intravenous immunoglobulin and sedation with 
midazolam was discontinued. She gradually started tracking objects and following 
commands but continued having partial seizures that were treated with carbamazepine 
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and gabapentin. On days 32 to 36, intravenous immunoglobulin administration was 
repeated, and by day 43, she was able to breathe spontaneously. By day 52, she was 
able to drink; the last seizure was observed on day 53. On day 64, she was eating 
regularly, and a few days later, she was able to walk. Her Mini-Mental State Examination 
score was 27 of 30 on day 85 and she was discharged home with minimal deficits on 
day 87. 
Case 3 
A 19-year-old pregnant woman presented at 17 weeks of gestation with acute-
onset behavioral change, including increasing nervousness, irritability, and anxiety. She 
stopped walking and communicating but would say the same word repetitively and was 
transferred to a psychiatric facility. Her bizarre behavior continued; for example, she was 
frequently hitting the walls, taking cold baths, and accusing the physicians of “being 
murderers.” She had fluctuating periods of decreased level of consciousness and 
agitation. She had a partial tonic seizure involving the left arm without EEG correlate; 
this showed generalized high-amplitude slow activity (2 Hz). Because of progressive 
deterioration and the presumptive diagnosis of viral encephalitis, she was transferred 1 
week later to a neurology unit. On physical examination, her temperature was 37.1°C, 
and she had no neck stiffness. She developed hyperhidrosis and repetitive semirhythmic 
oral movements, like automatisms. Brain computed tomography and MRI were normal. 
The CSF showed lymphocytic pleocytosis (white blood cell count, 11/μL) with normal 
protein and glucose concentrations. Results of extensive viral studies and autoimmune 
and paraneoplastic markers were negative. Anti-NMDAR antibodies were identified in 
her serum and CSF. A second EEG showed no changes compared with the previous 
study. Magnetic resonance imaging of the abdomen and pelvis and abdominal 
ultrasonography were normal. 
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From day 19, the patient was treated with intravenous methylprednisolone (500 
mg/d for 5 days) without clinical improvement, and a similar course of 
methylprednisolone treatment was started on day 35. After this second treatment, the 
orofacial dyskinesias subsided, but she continued with a decreased level of 
consciousness. On day 54, she had a generalized tonic-clonic seizure and treatment 
with phenobarbital was started. One month later, her level of consciousness started to 
progressively improve. Throughout the hospitalization, she did not develop 
hypoventilation. The fetus was monitored regularly by Doppler ultrasonography, showing 
normal heart tones. At 37 weeks of pregnancy, she spontaneously delivered a healthy 
2892-g baby with Apgar scores of 8 at 1 minute and 9 at 5 minutes. Her Mini-Mental 
State Examination score was 24 of 30, and she was discharged 3 weeks later. At the 
last follow-up, she was fully functional and had returned to work. The child remains 
healthy with no obvious adverse effects. 
Detection of NMDAR antibodies 
All 3 patients had higher NMDAR antibody titers in CSF than serum (Table). No 
antibodies were identified in the amniotic fluid, umbilical cord blood, serum, or CSF from 
the baby of patient 1. The baby of the other patient was not examined for antibodies. 
Comment 
To our knowledge, these are the first reported patients with anti-NMDAR 
encephalitis diagnosed during pregnancy. The 3 patients had substantial neurological 
recoveries, although in 1 case the pregnancy was terminated because of the severity of 
neurological symptoms, presence of recurrent bilateral teratomas, and early stage of 
pregnancy. The newborns of the other 2 patients were healthy and their physical and 
cognitive milestones are being closely followed up. Concern for the 
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fetus and newborns is warranted in this disorder as studies indicate that NR1 antibodies 
from patients decrease NMDAR clusters in vitro and in animal models (Dalmau et al., 
2008; Hughes et al., 2010). Moreover, the antibodies are IgG1 and IgG3, which are the 
subtypes involved in autoimmune newborn illnesses, such as congenital lupus (Hoftman 
et al., 2008). 
The good outcome of the 2 neonates of our study is likely due to several factors, 
including the variable effects of autoimmune disorders on the fetus. For example, 
despite experimental models showing that Ro/SSA antibodies cause congenital heart 
block, only 2% to 5% of neonates from patients with these antibodies have congenital 
heart block (Brucato et al., 2002). Two additional factors relate to the levels of serum 
maternal antibodies and the timing of transplacental transfer of IgG. IgG1 and IgG3 
cross the placenta by binding to an Fc neonatal receptor present in syncytiotrophoblasts 
(Roopenian and Akilesh, 2007). This mechanism of placental transfer develops around 
weeks 14 to 16, resulting initially in very low levels of fetal blood IgG that gradually 
increase until the time of delivery. Additionally, the fetal blood-brain barrier becomes 
functional by the end of the second trimester. Our patients developed symptoms 
between 8 and 17 weeks of pregnancy when the IgG placental transfer is absent or 
limited, and assuming the immune response was triggered systemically, the levels of 
serum NMDAR antibodies decreased rapidly. In fact, 2 patients had negative serum but 
positive CSF antibody titers (both tested at initial dilution 1:10) by the time they were 
diagnosed with anti-NMDAR encephalitis, explaining the absence of NMDAR antibodies 
in the baby who was tested. 
With a sharp increase in the number of cases with anti-NMDAR encephalitis, more 
patients will be identified during pregnancy. This study suggests that these patients and 
the newborns can do well. The concern should be the search (and 
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removal) of a teratoma along with supportive care of the mother and fetus. Treatment 
with corticosteroids, intravenous immunoglobulin, and plasmapheresis was well tolerated 
but the effects could not be assessed because of the close temporal association with 
tumor removal in 2 patients. The third patient only received corticosteroids, with 
questionable improvement of the dyskinesias. The recovery seemed to accelerate after 
giving birth; this and the predominance of the disorder in young women bring into 
consideration a possible role of hormonal factors that needs further study. 
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Figures 
Figure 1. Cardiac pauses and bilateral teratomas in patient 2.  
A, Cardiac pauses up to 5 seconds were noted on day 3 of hospital admission. B, A 
pelvic computed tomographic scan revealed bilateral recurrent teratomas (arrows).  
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CHAPTER 5. Conclusion 
Each of the clinical syndromes under the umbrella of autoimmune encephalitis is an 
opportunity to not only understand the mechanism by which the human body fails to 
distinguish self from non-self but also how autoantibodies cause neuropsychiatric 
disease.  The basic science and translational work on the unique aspects on each of the 
autoimmune encephalitides underscores that despite a failure in immunotolerance, 
cellular and humoral factors can disrupt their target antigen in distinct ways.  
Although the molecular and cellular effects of the antibodies are being rapidly 
resolved, the effects of the antibody-mediated disruption of synaptic proteins on network 
and circuit properties are still largely unknown. Extrapolating from the clinical effects of 
the pathogenic antibodies and from the known functions of the antigenic synaptic 
components, one can expect that in patients, circuit abnormalities such as altered 
excitation-inhibition balance, aberrant homeostatic synaptic scaling, loss of synaptic 
plasticity, reentrant feedback loops result in neuropsychiatric manifestations such as 
psychotic behavior, impaired memory formation, seizures or movement disorders. 
Studies in animal models and patients will provide insights into the circuit alterations 
caused by antibodies that result in aberrant behavior. 
A major gap in understanding of CNS autoimmune diseases exists in identification 
of mechanisms at the interface between the nervous and the immune systems. The 
current literature strongly supports the model that autoreactive T and B cells extravasate 
into the parenchymal and perivascular spaces in the CNS where they may survey the 
inflammatory state of the neuronal tissues that in turn affects the maturation of these 
lymphocytes. Our understanding of humoral inflammation and cell-
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mediated factors and their effects on neurons and glia is burgeoning, but is currently in 
its infancy.   
The mechanism by which GABAB autoantibodies result in disease is just beginning 
to be understood. Until this work, all autoimmune encephalitides described were 
associated with autoantibodies that reduced the levels of cognate receptors. I have 
shown that GABAB receptor autoantibodies directly block GABAB receptor activation by 
baclofen, suggesting that the clinical manifestations of GABAB receptor autoantibodies 
result from diminished GABAB receptor function. Patient GABAB receptor autoantibodies 
do not inactivate GABAB receptors, however, because the patient antibody mediated 
baclofen block was circumvented by directly activating the GABAB2 subunit with a 
selective partial allosteric agonist, CGP7930. This provides hope that newly developed 
brain penetrant GABAB2 agonists may be used to treat the intractable seizures that are 
the primary cause of morbidity and mortality in anti-GABAB receptor encephalitis 
patients. 
The Sushi domains present in the presynaptically localized GABAB(1a,2) receptors is 
the immunodominant domain recognized by GABAB receptor. How the binding to this 
domain blocks the activation of GABAB1 receptors by agonists is unclear. Currently, it is 
thought that the function of sushi domains is to target GABAB1a to the axonal domain of 
neurons. While patient autoantibodies are GABAB receptor antagonists, it is possible that 
autoantibodies also affect receptor trafficking and presynaptic localization by blocking 
the two Sushi domains. This can be tested by probing whether patient antibodies can 
result in a loss of polarity of the distribution a sushi domain containing peptide in cell 
culture. Our work raises the possibility that sushi domains may have functions other than 
polar trafficking that are important for the activation of GABAB1a receptors. Specifically, it 
would be valuable to demonstrate that GABAB autoantibodies block 
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GABAB1a containing receptors but not GABAB1b containing receptors. If this is true, the 
patient GABAB autoantibodies would be a valuable research tool to dissect the distinct 
contributions of GABAB1a and GABAB1b in GABA mediated neurotransmission, and be a 
model for therapeutic strategies that target GABAB1a mediated signaling but not GABAB1b 
mediated signaling.     
The development of the in vivo model of anti-NMDA receptor encephalits enables 
several lines of investigation, with relevance to both clinical management of this disease 
and our understanding of the role of NMDA receptors in circuits, cognition and behavior. 
A potential blocking peptide that disrupts the ability of the pathogenic antibody to bind to 
NMDA receptors can be studied. Also, the hypothesis that the Ephrin receptor 
interaction is necessary for the pathogenic effect of NMDA receptor autoantibodies can 
be tested.  
Infusion into the cerebral ventricles delivers the pathogenic antibody to nearly every 
brain structure, and it is unclear what circuits are compromised by the autoantibody to 
cause a decline in spatial object memory. Focused intraparenchymal infusion of patient 
CSF with concomitant electrophysiological recording will enable us to pinpoint the 
defects in circuit function and plasticity that underlies the currently observed spatial 
memory deficit.  
Understanding the mechanisms of recovery after widespread loss of NMDA 
receptors is of utmost clinical importance. Interestingly, clearance of anti-neuronal 
antibodies is not a good predictor of amelioration of symptoms. Long after antibodies are 
undetectable in serum or CSF, patients remain functionally compromised. It can take up 
to two years for a full return to work and normal routine and sometimes even years after 
treatment people are left with cognitive deficiencies. In culture, receptor levels return to 
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baseline 3-4 days after antibody removal and in the animal model, immunoglobulin 
clearance and recovery of NMDARs is complete within twelve days of cessation of 
antibody infusion. In patients’ brains, which may have been exposed to autoantibodies 
for months, the loss of NMDA-mediated glutamatergic transmission may have resulted in 
a cascade of changes, both within and between neurotransmitter systems. As antibody 
titers fall, even though receptor density returns to normal, the brain may require 
additional time to reset to its pre-disease baseline. The animal model can be used to 
probe changes in other neurotransmitter systems and kinetics of these changes that 
may hopefully shed light on the downstream effects of a global reduction in NMDA 
receptor functioning.  
These diseases offer human models of brain-immune interactions in which the 
target antigens have critical roles in neuronal synaptic transmission and plasticity.  
Patient antibodies have proven to be potent tools with no commercial equivalent that 
enable the roles of target proteins to be addressed at the synaptic, cellular, circuit and 
behavioral levels.  Studies of mechanisms underlying recovery of function as well as 
lingering effects on behavior as antibody titers are reduced will also be important.  
Ongoing work may lead to targeted therapeutic strategies for autoimmune encephalitis, 
and will also provide an unprecedented window into the in vivo role of key synaptic 
components essential for neuronal communication, circuit function and behavior. 
